UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.20549

FORM 10-Q

(Mark one)

[X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended NovemberJune 30, 20172023

[  ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 0-17284

AIXIN LIFE INTERNATIONAL, INC.

MERCARI COMMUNICATIONS GROUP, LTD.

(Exact name of registrant as specified in its charter)

Colorado84-1085935

(State or other jurisdiction of

of incorporation or organization)

(IRS Employer

Identification No.)

Hongxing International Business Building 2, 14th FL, No. 69 Qingyun South Ave., Jinjiang District

Chengdu City, Sichuan Province, China

(Address of principal executive offices)

1120 Avenue of the Americas, 4th floor, New York, NY 1003686-313-6732526

(Former Address of principal executive offices)

86-400-6260600

(Issuer’s telephone number)

Securities Registered Pursuant to Section 12(g) of the Act:

Title of Each ClassTrading Symbol(s)Name of each Exchange on which Registered
Common Stock, $0.00001 Par ValueAIXNOTCQX

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer[  ]Accelerated filer[  ]
Non-accelerated filer[  ](Do not check if a smaller reporting company)Smaller reporting company[X]
Emerging growth company[X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [X] No [  ]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practical date: As of January 5, 2018,August 11, 2023, there were outstanding 317,988,08924,999,842 shares of the registrant’s common stock.

 

 

MERCARI COMMUNICATIONS GROUP, LTD.

FORM 10-Q

November 30, 2017

INDEX

 

AIXIN LIFE INTERNATIONAL, INC.

FORM 10-Q

June 30, 2023

INDEX

Page
Cautionary StatementSpecial Note Regarding Forward-looking InformationForward Looking Statements3
Part I – Financial Information4
Item 1.CondensedConsolidated Financial Statements4
CondensedConsolidated Balance Sheets4
CondensedConsolidated Statements of Operations and Comprehensive Income (Loss)5
CondensedConsolidated Statements of Stockholders’ Equity6
Consolidated Statements of Cash Flows67
Notes to CondensedConsolidated Financial Statements78
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations1328
Item 3.Quantitative And Qualitative Disclosures About Market Risk15
Item 4.Controls and Procedures1538
Part II – Other Information39
Item 1.Legal Proceedings16
Item 1A.Risk Factors1639
Item 2.6.Unregistered Sales of Equity Securities and Use of ProceedsExhibits1639
Item 3.Defaults Upon Senior Securities16
Item 4.Mine Safety Disclosures16
Item 5.Other Information16
Item 6.Exhibits17
Signatures1840

2

 

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
INFORMATION

This Quarterly Reportreport contains forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about Mercari Communications Group, Ltd. (the “Company,” “Mercari,” “we,” “us,”assumptions and “our”) that are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on forward-looking statements. Forward-looking statements include, information concerning future financial performance, business strategy, projected plans and objectives. Statements preceded by, followed by or that otherwise include the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “may increase,” “may fluctuate” and similar expressions of future or conditional verbs such as “will,” “should,” “would,” and “could” are generally forward-lookingamong other things, statements relating to:

our goals and strategies;
our future business development, financial condition and results of operations;
our expectations regarding demand for, and market acceptance of, our products;
our expectations regarding keeping and strengthening our relationships with merchants, manufacturers and end-users; and
general economic and business conditions in nature and not historical facts. Actual results may differ materially from those projected, implied, anticipated or expected in the forward-looking statements. Readers of this Quarterly Report should not rely solely on the regions where we provide our services.

Also, forward-looking statements represent our estimates and should consider all uncertainties and risks throughout this report. The statements are representativeassumptions only as of the date they are made. The Company undertakesof this report. You should read this report and the documents that we reference and filed as exhibits to the report completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update any forward-looking statement.

These forward-looking statements implicitly and explicitly, includepublicly, or to update the assumptions underlying the statements and other information with respect to the Company’s beliefs, plans, objectives, goals, expectations, anticipations, estimates, financial condition, results of operations, future performance and business, including management’s expectations and estimates with respect to revenues, expenses, return on equity, return on assets, asset quality and other financial data.

Although the Company believes the expectations reflected in the forward-looking statements are reasonable, these statements involve risks and uncertainties that are subject to change based on various important factors, some of which are beyond the control of the Company. The following factors, among others, could cause the Company’s results or financial performance to differ materially from its goals, plans, objectives, intentions, expectations and other forward-looking statements:

general economic and industry conditions;
limited resources and need for additional financing;
competition for suitable private companies with which to merge;
no definitive agreements or business opportunities identified;
substantial dilution to current shareholders if a merger occurs; and
our stock is thinly traded with limited liquidity.

All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update this Quarterly Report on Form 10-Q to reflect events or circumstances after the date hereof. New factors emerge from time to time, and it is not possible for us to predict which factors, if any, will arise. In addition, the Company cannot assess the impact of each factor on the Company’s business or the extent to which any factor, or combination of factors, may causereasons actual results tocould differ materially from those containedanticipated in any forward-looking statements.statements, even if new information becomes available in the future.

Use of Certain Defined Terms

Except where the context otherwise requires and for the purposes of this report only:

the “Company,” “we,” “us,” and “our” refer to AiXin Life International., Inc. (“AiXin”) and its subsidiaries.

“Exchange Act” refers to the Securities Exchange Act of 1934, as amended;

“Hong Kong” refers to the Hong Kong Special Administrative Region of the People’s Republic of China;

“PRC,” “China,” and “Chinese,” refer to the People’s Republic of China (excluding Hong Kong and Taiwan);

“Renminbi” and “RMB” refer to the legal currency of China;

“Securities Act” refers to the Securities Act of 1933, as amended; and

“US dollars,” “dollars” and “$” refer to the legal currency of the United States.

3

 

PART I - FINANCIAL INFORMATION

Item 1. Financial StatementsAIXIN LIFE INTERNATIONAL, INC.

MERCARI COMMUNICATIONS GROUP, LTD

CONSOLIDATED BALANCE SHEETS

  November 30, 2017 (Unaudited)  May 31, 2017 (Audited) 
       
ASSETS        
         
CURRENT ASSETS        
Cash $-  $- 
         
Total assets     $- 
         
LIABILITIES AND STOCKHOLDERS’ DEFICIT        
         
CURRENT LIABILITIES        
Accounts payable and accrued liabilities $5,528  $38,228 
Due to third party  5,500   - 
Due to related parties  248,265   166,677 
         
Total liabilities  259,292   204,905 
         
STOCKHOLDERS’ DEFICIT        
Common stock, par value $0.0001 per share, 950,000,000 shares authorized; 45,411,400 shares issued and outstanding  454   454 
Additional paid in capital  158,722   158,722 
Accumulated deficit  (418,468)  (364,081)
         
Total stockholders’ deficit  (259,292)  (204,905)
         
TOTAL LIABILITIES AND DEFICIT $-  $- 
  June 30,  December 31, 
  2023  2022 
  (Unaudited)    
       
Assets        
Current assets        
Cash and cash equivalents $316,905  $510,128 
Restricted cash  97,625   109,772 
Accounts receivable, including related parties, net  345,500   562,581 
Other receivables and prepaid expenses  66,331   42,631 
Advances to suppliers, including related party  156,745   168,523 
Inventory, net  625,752   499,252 
Due from related parties  134,320   83,102 
Total current assets  1,743,178   1,975,989 
         
Property and equipment, net  1,701,307   1,971,793 
Intangible asset, net  3,241   1,269 
Goodwill, net  -   - 
Deferred tax asset  13,934   15,556 
Security deposit  82,744   86,992 
Operating lease right-of-use assets  682,694   999,285 
Total assets $4,227,098  $5,050,884 
         
Liabilities and stockholders’ equity        
Current liabilities        
Accounts payable $470,770  $398,469 
Accounts payable-related party  -   165,958 
Unearned revenue  126,484   139,502 
Taxes payable  103,636   104,100 
Accrued liabilities and other payables  2,143,431   2,356,490 
Government grant  903,962   950,371 
Loan from third parties  82,744   86,992 
Operating lease liabilities  601,626   883,583 
Due to related parties  204,443   236,882 
Total current liabilities  4,637,096   5,322,347 
Operating lease liabilities - non-current  205,903   194,725 
Total liabilities  4,842,999   5,517,072 
         
Stockholders’ deficit        
Undesignated preferred stock, $0.001 par value, 20,000,000 shares authorized, none issued and outstanding  -   - 
Common stock, par value $0.00001 per share, 500,000,000 shares authorized; 24,999,842 shares issued and outstanding as of June 30, 2023 and December 31, 2022  250   250 
Additional paid in capital  14,789,653   14,458,583 
Statutory reserve  151,988   151,988 
Accumulated deficit  (15,757,028)  (15,249,858)
Accumulated other comprehensive income  199,236   172,849 
Total stockholders’ deficit  (615,901)  (466,188)
         
Total liabilities and stockholders’ deficit $4,227,098  $5,050,884 

The accompanying notes are an integral part of these financial statements.

4

 

MERCARI COMMUNICATIONS GROUP, LTDAIXIN LIFE INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

  For The Six Months Ended November 30,  For The Three Months Ended November 30, 
  2017  2016  2017  2016 
             
Revenue $-  $-  $-  $- 
                 
Expenses                
General and administrative  54,387   20,869   20,500   11,949 
                 
Net loss $(54,387) $(20,869) $(20,500) $(11,949)
                 
Basic and diluted loss per share $(0.001) $(0.0005)  (0.000)  (0.0003)
                 
Weighted average shares  45,411,400   45,411,400  $45,411,400  $45,411,400 
  2023  2022  2023  2022 
  

Three Months Ended

June 30,

  

Six Months Ended

June 30,

 
  2023  2022  2023  2022 
             
Sales revenue:                
Products $1,085,527  $210,636  $1,507,823  $385,628 
Room revenues  221,643   63,723   398,902   94,716 
Food and beverage revenues  144,747   111,725   278,485   292,519 
Others  24,140   34,803   45,560   66,702 
Total revenue, net  1,476,057   420,887   2,230,770   839,565 
                 
Operating costs and expenses                
Cost of goods sold  451,200   153,998   626,688   278,522 
Hotel operating costs  462,780   418,100   940,574   929,719 
Selling  226,575   200,032   417,848   389,618 
General and administrative  355,422   274,675   768,481   519,471 
(Reversal of) provision for bad debts  (8,037)  20,435   (51,853)  47,857 
Stock-based compensation  92,885   92,885   185,770   185,770 
Total operating costs and expenses  1,580,825   1,160,125   2,887,508   2,350,957 
                 
Loss from operations  (104,768)  (739,238)  (656,738)  (1,511,392)
                 
Non-operating income (expenses)                
Interest income  268   1,284   557   2,612 
Other income  14,241   10,221   39,102   29,655 
Other expenses  (2,380)  (63)  (4,887)  (260)
Total non-operating income, net  12,129   11,442   34,772   32,007 
                 
Loss before income tax  (92,639)  (727,796)  (621,966)  (1,479,385)
                 
Income tax expense  4,907   473   5,364   965 
                 
Net loss  (97,546)  (728,269)  (627,330)  (1,480,350)
                 
Other comprehensive items                

Foreign currency translation gain (loss)

  1,845   (44,948)  26,387   (13,084)
                 
Comprehensive loss $(95,701) $(773,217) $(600,943) $(1,493,434)
                 
Income per share - basic and diluted $(0.004) $(0.029) $(0.025) $(0.059)
                 
Weighted average shares outstanding  24,999,842   24,999,842   24,999,842   24,999,842 

The accompanying notes are an integral part of these financial statements.

5

 

MERCARI COMMUNICATIONS GROUP, LTDAIXIN LIFE INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWSSTOCKHOLDERS’ EQUITY (DEFICIT)

(UNAUDITED)

  FOR THE SIX MONTHS ENDED NOVEMBER 30, 
  2017  2016 
       
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss $(54,387) $(20,869)
Change in operating assets and liabilities        
Accounts payable and accrued liabilities  (32,701)  (2,368)
         
Net cash used in operating activities  (87,088)  (23,237)
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Due to third party  5,500   - 
Due to related parties  81,588   22,100 
         
Net cash provided by financing activities  87,088   22,100 
         
NET INCREASE IN CASH AND CASH EQUIVALENTS  -   (1,137)
         
CASH AT THE BEGINNING OF PERIOD  -   1,765 
         
CASH AT THE END OF PERIOD $-  $628 
  Shares  Amount  capital  reserves  deficit  income  Total 
  Common Stock  Additional paid in  Statutory  Accumulated  Accumulated other comprehensive    
  Shares  Amount  capital  reserves  deficit  income  Total 
                      
Balance at December 31, 2022  24,999,842  $250  $14,458,583  $151,988  $(15,249,858) $172,849  $(466,188)
Stock-based compensation  -   -   92,885   -   -   -   92,885 
Disposal of subsidiary  -   -   -   -   120,160   -   120,160 
Net loss  -   -   -   -   (529,784)  -   (529,784)
Foreign currency translation  -   -   -   -   -   24,542   24,542 
Balance at March 31, 2023  24,999,842   250   14,551,468   151,988   (15,659,482)  197,391   (758,385)
Stock-based compensation  -   -   92,885   -   -   -   92,885 
Capital contribution  -   -   145,300   -   -   -   145,300 
Net loss  -   -   -   -   (97,546)  -   (97,546)
Foreign currency translation  -   -   -   -   -   1,845   1,845 
Balance at June 30, 2023  24,999,842  $250  $14,789,653  $151,988  $(15,757,028) $199,236  $(615,901)
                             
Balance at December 31, 2021  24,999,842  $250  $14,087,043  $151,988  $(8,880,613) $710,823  $6,069,491 
Stock-based compensation  -   -   92,885   -   -   -   92,885 
Net loss  -   -   -   -   (752,081)  -   (752,081)
Foreign currency translation  -   -   -   -   -   31,864   31,864 
Balance at March 31, 2022  24,999,842   250   14,179,928   151,988   (9,632,694)  742,687   5,442,159 
Beginning balance value  24,999,842   250   14,179,928   151,988   (9,632,694)  742,687   5,442,159 
Stock-based compensation  -   -   92,885   -   -   -   92,885 
Net loss  -   -   -   -   (728,269)  -   (728,269)
Foreign currency translation  -   -   -   -   -   (44,948)  (44,948)
Balance at June 30, 2022  24,999,842  $250  $14,272,813  $151,988  $(10,360,963) $697,739  $4,761,827 
Ending balance value  24,999,842  $250  $14,272,813  $151,988  $(10,360,963) $697,739  $4,761,827 

The accompanying notes are an integral part of these financial statements.

6

 

AIXIN LIFE INTERNATIONAL, INC.

MERCARI COMMUNICATIONS GROUP, LTD.CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

  2023  2022 
  Six Months Ended June 30, 
  2023  2022 
       
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss $(627,330) $(1,480,350)
Adjustments required to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization  193,427   57,219 
(Reversal of) provision for bad debts  (51,853)  47,857 
Provision for inventory reserve  12,026   - 
Operating lease expense  417,369   449,445 
Stock-based compensation  185,770   185,770 
Deferred tax  902   965 
Changes in assets and liabilities:        
Accounts receivable  249,851   (65,284)
Other receivables and prepaid expenses  (46,276)  92,619 
Advances to suppliers, including related party  24,890   12,043 
Inventory  (170,052)  (72,168)
Accounts payable  98,150   89,349 
Accounts payable - related party  (165,172)  - 
Unearned revenue  (6,552)  (10,099)
Taxes payable  4,839   (7,034)
Payment of lease liability  (405,079)  (418,711)
Accrued liabilities and other payables  (65,670)  346,883 
Net cash used in operating activities  (350,760)  (771,496)
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Cash disposed at disposal of subsidiary  (3,392)  - 
Purchase of property and equipment  (10,627)  - 
Purchase of intangible asset  (2,647)  - 
Net cash used in investing activities  (16,666)  - 
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Net proceeds from related parties  39,677   779,015 
Capital contribution  144,300   - 
Net cash provided by financing activities  183,977   779,015 
         
EFFECT OF EXCHANGE RATE CHANGE ON CASH AND RESTRICTED CASH  (21,921)  (417,088)
         
NET DECREASE IN CASH AND RESTRICTED CASH  (205,370)  (409,569)
         
CASH AND RESTRICTED CASH, BEGINNING OF PERIOD  619,900   8,600,853 
         
CASH AND RESTRICTED CASH, END OF PERIOD $414,530  $8,191,284 
         
Supplemental Cash flow data:        
Income tax paid $-  $- 
Interest paid $-  $- 

7

AIXIN LIFE INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOVEMBER 30, 2017 (UNAUDITED) AND MAY 31, 2017

 

NOTE 1 - 1. ORGANIZATION AND SUMMARYDESCRIPTION OF SIGNIFICANT ACCOUNTING POLICIESBUSINESS

 

Organization

Mercari Communications Group, Ltd.Aixin Life International, Inc. (the “Company” or “Aixin Life” or “we”) was incorporated under the laws of the State of Colorado on December 30, 1987. From 1988 until 1990,On February 2, 2017, Mr. Quanzhong Lin (Mr. Lin) purchased 65.0% of the Company’s outstanding shares from China Concentric Capital Group for $300,000, pursuant to a Stock Purchase Agreement dated December 21, 2016, which resulted in a change in control of the Company.

On December 12, 2017, pursuant to a Share Exchange Agreement, in consideration for all of the outstanding shares of AiXin (BVI) International Group Co., Ltd. a British Virgin Islands corporation (“AiXin BVI”), the Company provided educationalissued to Mr. Lin, the sole stockholder of AiXin BVI, shares of common stock then representing 71% of the outstanding of common stock of the Company.

As a result of the Share Exchange, AiXin BVI became the Company’s wholly-owned subsidiary, and the Company now owns all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”), which in turn owns all of the outstanding shares of Chengdu AiXinZhonghong Biological Technology Co., Ltd., a Chinese limited company (“AiXinZhonghong”), which markets and sells premium-quality nutritional products counseling, seminar programs,in China.

AiXin BVI was incorporated on September 21, 2017 as a holding company and publicationsAiXin HK was established in Hong Kong on February 25, 2016 as an intermediate holding company. AiXinZhonghong was established in the People’s Republic of China (“PRC”) on March 4, 2013, and on May 27, 2017, the local government of the PRC issued a certificate of approval regarding the foreign ownership of AiXinZhonghong by AiXin HK. Neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017.

For accounting purposes, the acquisition of AiXin BVI was accounted for as a reverse acquisition and treated as a recapitalization of the Company effected by a share exchange, with AiXin BVI as the accounting acquirer. Since neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017, the historical consolidated financial statements of AiXinZhonghong are now the historical consolidated financial statements of the Company. The assets and liabilities of AiXinZhonghong were brought forward at their book value and no goodwill was recognized.

Effective February 1, 2018, the Company changed its name to AiXin Life International, Inc. (“Aixin Life”).

The Company, through its indirectly owned AiXinZhonghong subsidiary, develops and distributes consumer products by offering a line of nutritional products. The Company sells the products through exhibition events, conferences, and person-to-person marketing. Beginning in 2019, the Company began to provide advertising services to clients who engaged the Company to help distribute their products. The Company’s business mainly focuses on a proactive approach to its customers such as newslettershosting events for clients, which it believes is ideally suited to adults agedmarketing its products because sales of nutrition products are strengthened by ongoing personal contact and support, coaching and education of its clients, as to the benefits of a healthy and active lifestyle.

On May 25, 2021, AiXin HK entered into an Equity Transfer Agreement (the “Hotel Purchase Agreement”) with Chengdu Aixin Shangyan Hotel Management Co., Ltd (“Aixin Shangyan Hotel”), and its two shareholders Quanzhong Lin and Yirong Shen (“Transferor”). Pursuant to the Hotel Purchase Agreement, Aixin Life purchased 100% ownership of Aixin Shangyan Hotel from Transferor. Eighty percent of the equity of Aixin Shangyan Hotel was owned by Mr. Lin, and the remaining balance was owned by Ms. Shen. Under the terms of the Hotel Purchase Agreement, Aixin Life purchased all of the outstanding equity of Aixin Shangyan Hotel for a purchase price of RMB 7,598,887, or approximately $1.16 million (the “Transfer Price”). The Transfer Price will be reduced by an amount equal to any amounts paid or distributed by Aixin Shangyan Hotel to the Transferor after December 31, 2020 and will be increased by an amount equal to any amounts contributed to Aixin Shangyan Hotel by the Transferor after December 31, 2020. The acquisition was completed in July 2021.

8

On June 2, 2021, AiXin HK entered into an Equity Transfer Agreement (the “Pharmacies Purchase Agreement”) with Chengdu Aixintang Pharmacy Co., Ltd. and certain affiliated entities, each of which operates a pharmacy (together, “Aixintang Pharmacies”) and its three shareholders, Quanzhong Lin, Ting Li and Xiao Ling Li (“Transferor”). Mr. Lin owned in excess of 95% of the outstanding equity the Aixintang Pharmacies. The remaining equity interest was owned by Ting Li and Xiao Ling Li. Pursuant to the Pharmacies Purchase Agreement, AiXin HK purchased all of the outstanding equity of Aixintang Pharmacies for an aggregate purchase price of RMB 34,635,845, or approximately US$5.31 million (the “Transfer Price”). The Transfer Price will be reduced by an amount equal to any amounts paid or distributed by any of the Aixintang Pharmacies to the Transferor after December 31, 2020 and increased by an amount contributed to any of the Aixintang Pharmacies by the Transferor after such date. The acquisition was completed in September 2021.

On July 19, 2022, HK Aixin entered into an Equity Transfer Agreement with Yunnan Shengshengyuan Technology Co., Ltd, (“Yunnan Shengshengyuan”) and Yun Chen (together, the “Sellers”), the shareholders of Yunnan Runcangsheng Technology Company Ltd. (“Runcangsheng”). Yunnan Shengshengyuan owns in excess of 95% of the outstanding equity of Runcangsheng. The remaining equity interest is owned by Yun Chen. Pursuant to the Transfer Agreement, HK Aixin agreed to purchase all of the outstanding equity of Runcangsheng for an aggregate purchase price of $4,418,095 (RMB 31,557,820), adjusted by $116,802 the amount equal to the initial net worth minus the audited net worth. In addition to transferring their respective equity interest in Runcangsheng by the Sellers, both Sellers agree to forgive any loans Runcangsheng due to them. The acquisition was completed on September 30, to 50.2022 (see Note 17).

On February 17, 2023, the Company effected a 1 for 2 reverse stock split. As a result of the reverse split, every two shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.00001 per share. The Company financedhas approximately 24,999,842 shares of outstanding common stock after the effect of reverse stock split and the elimination of fractional shares. All share and earnings per share information has been retroactively adjusted to reflect the reverse stock split.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”). The functional currency of AiXinZhonghong, Aixin Shangyan Hotel, Aixintang Pharmacies, and Runcangsheng is the Chinese Renminbi (“RMB”). The accompanying consolidated financial statements are translated from RMB and presented in U.S. dollars (“USD”).

The consolidated financial statements include the accounts of the Company and its businesscurrent wholly owned subsidiaries, AiXin HK, AiXinZhonghong, Aixin Shangyan Hotel, Aixintang Pharmacies, and Runcangsheng. Intercompany transactions and accounts were eliminated in consolidation. These unaudited interim financial statements should be read in conjunction with private offeringsthe annual consolidated financial statements and the accompanying notes contained in our Annual Report on Form 10-K for the year ended December 31, 2022.

Unaudited Interim Financial Information

These unaudited interim financial statements have been prepared in accordance with GAAP for interim financial reporting and the rules and regulations of securities, shareholder loans, and with an underwritten initial public offering of securities registered with the Securities and Exchange Commission (“SEC”). The Company’s business failedthat permit reduced disclosure for interim periods. Therefore, certain information and footnote disclosures normally included in 1990. The Company ceasedfinancial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of management, all operations from 1990 to 2001 and was dormant. During the period the Company was dormant, it did not file required reports with the SEC under the Securities Exchange Actadjustments of 1934, as amended (“Exchange Act”). On August 3, 2004, the shareholdersa normal recurring nature necessary for a fair presentation of the Company approved a planfinancial position, results of quasi-reorganization which calledoperations and cash flows for a restatementthe periods presented have been made. The results of accountsoperations for the interim periods presented are not necessarily indicative of the results to eliminatebe expected for the accumulated deficit and related capital accounts on the Company’s balance sheet. The quasi-reorganization was effective March 1, 2004. Since March 1, 2004, the Company is in the development stage, and has not commenced planned principal operations. The Company has no products or services as of November 30, 2017.year ending December 31, 2023.

9

Going Concern

 

Going Concern

The accompanying consolidated financial statements werehave been prepared on a going concern basis, which contemplates the basisrealization of accounting principles applicable to a “going concern”, which assume that the Company will continue in operation for at least one year and will be able to realize its assets and discharge itsthe satisfaction of liabilities in the normal course of operations.business. The realization of assets and the satisfaction of liabilities in the normal course of business are dependent on, among other things, the Company’s ability to operate profitably, to generate cash flows from operations, and to pursue financing arrangements to support its working capital requirements.

 

SeveralThe Company has suffered losses from operations of $104,768 and $739,238 for the three months ended June 30, 2023 and 2022, and $656,738 and $1,511,392 for the six months ended June 30, 2023 and 2022, respectively, and used net cash in operating activities of $350,760 and $771,496 for the six months ended June 30, 2023 and 2022, respectively, and has an accumulated deficit of $15,757,028 as of June 30, 2023. These facts and conditions and events castraise substantial doubt about the Company’s ability to continue as a “goinggoing concern.” The Company has incurred net From January 1, 2023 through June 30, 2023, the Company’s cash and cash equivalents decreased from $510,128 to $316,905 mainly due to operating losses, of $54,387 for and the six months ended November 30, 2017, has no revenues and requires additional financing in orderuse of cash to finance its business activities on an ongoing basis. The Company’s future capital requirements will depend on numerous factors including, but not limited to, continued progress in finding a merger candidate and the pursuit of business opportunities. In the interim, shareholders of the Company have been contributing capital to the Company to meet its ordinary and normalsupport operating expenses. activities.

Management believes that actions presently being takenit has developed a liquidity plan, summarized below, that, if executed successfully, should provide sufficient liquidity to revisemeet the Company’s obligations as they become due for a reasonable period of time, and allow the development of its core business. The plan includes:

● Gaining positive cash-inflow from operating activities through continuous cost reductions and the sales of higher margin products.

● Raising cash through loans from related parties and potential equity offerings.

While the Company’s management believes that the measures in its liquidity plan including those described above will be adequate to satisfy its liquidity requirements for the twelve months after the date that these financial statements are issued, there is no assurance that the liquidity plan will be successfully implemented. Failure to successfully implement the liquidity plan may have a material adverse effect on its business, results of operations and financial requirements provide it with the opportunityposition, and may adversely affect its ability to continue as a “going concern”.

going concern. These consolidated financial statements do not reflectinclude any adjustments related to the recoverability and classification of recorded assets or the amounts and classification of liabilities or any other adjustments that wouldmight be necessary ifshould the Company werebe unable to continue as a “going concern”. While management believesgoing concern.

The Invasion of Ukraine

The invasion of Ukraine by the actions already taken or planned, will mitigateRussian Federation had an immediate impact on the conditionsglobal economy resulting in higher prices for oil and events which raise doubt about the validityother commodities. The United States, United Kingdom, European Union and other countries responded to Russia’s invasion of the “going concern” assumption used in preparingUkraine by imposing various economic sanctions and bans. Russia has responded with its own retaliatory measures. These measures have disrupted financial and economic markets. The global impact of these financial statements,measures is continually evolving and cannot be predicted with certainty and there can beis no assurance these actionsthat Russia’s invasion of Ukraine and responses thereto will be successful. Ifnot further disrupt the Company were unable to continue as a “going concern,” then substantial adjustments would be necessary to the carrying values of assets, the reported amounts of its liabilities, the reported revenuesglobal economy and expenses, and the balance sheet classifications used.financial markets.

 

BasisWhile the invasion of PresentationUkraine and responses thereto have not interrupted the Company’s operations, these or future developments resulting from the invasion of Ukraine could make it difficult to access debt and equity capital on attractive terms, if at all, and impact the Company’s ability to fund business activities, including proposed acquisitions.

 

The financial statements were prepared in conformity with accounting principles generally accepted in the United StatesUse of America (“US GAAP”) and pursuant to the rules and regulations of the SEC for annual financial statements.Estimates

 

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.

7

Use of Estimates

The preparation ofIn preparing consolidated financial statements in conformity with US GAAP, required management to makemakes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosuredisclosures of contingent assets and liabilities at the datedates of the consolidated financial statements, andas well as the reported amounts of revenues and expenses during the reporting period.

Significant estimates required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

10

Reclassification

 

Development Stage CompanyCertain prior period amounts have been reclassified to conform to the current period presentation and had no effect on previously reported consolidated net income (loss) or accumulated deficit.

 

The Company is a development stage company as defined by section 915-10-20 of the FASB Accounting Standards Codification (“ASC”). Although the Company has recognized nominal amounts of revenue, it is still devoting substantially all of its efforts on establishing the business. All losses accumulated since its inception on March 1, 2004 were considered part of the Company’s development stage activities.Cash and Cash Equivalents

 

In June 2014,For financial statement purposes, the FASB issued Accounting Standards Update (“ASU”) No. 2014-10, Development Stage Entities (Topic 915): EliminationCompany considers all highly liquid investments with an original maturity of Certain Financial Reporting Requirements, Including an Amendmentthree months or less to Variable Interest Entities Guidance in Topic 810, Consolidation.be cash and cash equivalents.

 

Restricted Cash

The amendmentsrestricted cash was cash maintained in this ASU removetemporarily frozen bank accounts held by Aixintang Pharmacy and its branches by the definitioncourt for a judgement against Aixintang Pharmacy which Aixintang Pharmacy is in the process of appealing (see Note 16 – litigation).

Accounts Receivable

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of June 30, 2023 and December 31, 2022, the bad debt allowance was $200,044 and $272,550 respectively.

The following table summarizes the activity related to the Company’s Accounts Receivable allowance for doubtful accounts for the six months ended June 30, 2023 and 2022:

SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE FOR DOUBTFUL ACCOUNTS

  2023  2022 
  For the Six Months ended June 30, 
  2023  2022 
       
Beginning balance $272,550  $213,787 
(Reversal of) provision for bad debts  -   47,857 
Recoveries/Write offs  (51,853)  - 
Effect of translation  (20,653)  (11,933)
Ending balance $200,044  $249,711 

Inventories

Inventories mainly consists of health supplements, drugs, pharmaceutical and nutritional products, food and beverage, hotel supplies and consumables. Inventories are valued at the lower of average cost or market, cost being determined on a development stage entitymoving weighted average method at the end of the month. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down inventories to market value, if lower. The Company recorded provision for inventory reserve of $12,026 and $0 for the six months ended June 30, 2023 and 2022, respectively.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the Master Glossaryrespective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with 5% salvage value and estimated lives as follows:

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED LIVES

Office furniture5 years
Electronic equipment2-3 years
Machinery3 years
Leasehold improvements3 years
Vehicles5 years

11

Impairment of Long-Lived Assets

Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, but at least annually.

Recoverability of long-lived assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the Accounting Standards Codification, thereby removingasset exceeds its fair value. Fair value is generally determined using the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income,asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of June 30, 2023 and shareholder equity, (2) label the financial statements as thoseDecember 31, 2022, there were no significant impairments of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.its long-lived assets.

 

For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. The Company adopted ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the Company to remove the inception to date information and all references to the development stage.Goodwill

 

Income Taxes

The Company accountsevaluates goodwill for income taxes under Section 740-10-30 ofimpairment annually or more frequently when an event occurs or circumstances change that indicate the FASB ASC, which requires recognition of deferred tax assets and liabilitiescarrying value may not be recoverable. In testing goodwill for impairment, the expected future tax consequences of events that have been included in the financial statements or tax returns.

Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expectedCompany may elect to reverse. Deferred tax assets are reduced byutilize a valuation allowancequalitative assessment to the extent management concludesevaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets willto the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not be realized. Deferredthat goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.

The Company completed the required testing of goodwill for impairment as of December 31, 2022, and determined that goodwill was impaired because of the current financial condition of the Company and the Company’s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the uncertainty of the future cash flows indicates that the recoverability of goodwill is not reasonably assured.

The goodwill write-down was reflected as an impairment loss, $3,823,770, in non-operating expenses in the statement of operations and comprehensive income (loss) during the year ended December 31, 2022.

Income Taxes

Income taxes are accounted for using an asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities are measured usingand their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, expectedapplicable to apply to taxable income in the yearsperiods in which those temporarythe differences are expected to be recovered or settled. The effect onaffect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date.

The estimated future tax effects of temporary differences between the tax basis of assets and liabilities are reported in the accompanying balance sheets, as well as tax credit carry-backs and carry-forwards. The Company periodically reviews the recoverability of deferred tax assets recorded on its balance sheets and provides valuation allowances as management deems necessary.

Management makes judgments as to the interpretation of the tax laws that mightamount expected to be challenged upon an audit and cause changes to previous estimates of tax liability. In addition, the Company operates within multiple taxing jurisdictions and is subject to audit in these jurisdictions. In management’s opinion, adequate provisions for income taxes have been made for all years. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.realized.

 

812

 

 

Uncertain Tax Positions

The Company follows paragraph 740-10-25Accounting Standards Codification (“ASC”) Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of the FASB ASC. Paragraph 740-10-25-13 addresses the determination of whethera tax benefits claimedposition taken or expected to be claimed ontaken in a tax return shouldreturn. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

Under ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be recordedsustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements. Under paragraph 740-10-25-13,statements in the Company may recognize the tax benefit from an uncertain tax position only ifperiod during which, based on all available evidence, management believes it is more likely than not that the tax position will be sustained onupon examination, byincluding the taxing authorities, based onresolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the technical merits of the position. The tax benefits recognized in the financial statements from such a position should bemore-likely-than-not recognition threshold are measured based onas the largest amount of tax benefit that has a greateris more than 50% likelihoodlikely of being realized upon ultimate settlement.settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits areis classified as interest expense and penalties are classified in selling, general and administrative expenses in the statementsstatement of income.

 

TheAt June 30, 2023 and December 31, 2022, the Company did not take any uncertain positions that would necessitate recording a tax positionsrelated liability.

Revenue Recognition

Revenue from sale of goods under Topic 606 is recognized in a manner that reasonably reflects the delivery of the Company’s products and hadservices to customers in return for expected consideration and includes the following elements:

executed contract(s) with customers that the Company believes is legally enforceable;
identification of performance obligation in the respective contract;
determination of the transaction price for each performance obligation in the respective contract;
allocation of the transaction price to each performance obligation; and
recognition of revenue only when the Company satisfies each performance obligation.

The Company’s revenue recognition policies for its various operating segments are as follows:

Products

The Company’s revenue from sales of products is recognized when goods are delivered to the customer and no unrecognized tax liabilitiesother obligation exists. The Company does not provide unconditional return or benefits in accordanceother concessions to the customer. The Company’s sales policy allows for the return of unopened products for cash after deducting certain service and transaction fees. As an alternative to the product return option, the customers have the option of asking for an exchange for products with the provisionssame value.

Sales revenue of Section 740-10-25AiXin Zhonghong represents the invoiced value of goods, net of value-added taxes (“VAT”). All of the Company’s products sold in China are subject to the PRC VAT of 13% since April 1, 2019. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China. The Company records VAT payable and VAT receivable net of payments in the financial statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as the Company acts as an agent for the government.

13

Hotel

Hotel revenues are primarily derived from the rental of rooms, food and beverage sales and other ancillary goods and services, including but not limited to souvenir, parking and conference reservation. Each of these products and services represents a distinct performance obligation and, in exchange for these services, the Company receives fixed amounts based on published rates or negotiated contracts. Payment is due in full at November 30, 2017the time when the services are rendered or May 31, 2017. the goods are provided. Room rental revenue is recognized on a daily basis when rooms are occupied. Food and beverage revenue and other goods and services revenue are recognized when they have been delivered or rendered to the guests as the respective performance obligations are satisfied. All of the hotel’s goods sold in China are subject to the PRC VAT of 6%. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China.

Pharmacies

The tax years 2014-2016 remain openCompany’s retail drugstores (Aixintang Pharmacies) recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation. Aixintang Pharmacies generally receives payments from customers as it satisfies its performance obligations. The Company records a receivable when it has an unconditional right to examinationreceive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of VAT. All of Aixintang Pharmacies’ products sold in China are eligible for federal income tax purposesthe PRC VAT of 0% as it qualifies as a small business.

Manufacture and Sale

The Company’s new subsidiary Runcangsheng recognizes revenue at the time products are shipped as this satisfies its performance obligation. The Company records a receivable for its sales when it has an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of the Company’s products sold in China are subject to the PRC VAT of 13% unless it is a qualified small business subject to exemption.

Unearned Revenue

The Company’s unearned revenue primarily consists of advances received from customers for the purchase of products prior to the delivery of goods, and for the rental of hotel rooms prior to the delivery of service. The delivery of products and room rental services is (normally within one year) based upon contract terms and customer demand.

Concentration of Credit Risk

The operations of the Company are in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC economy.

The Company has cash on hand and demand deposits in accounts maintained with state-owned banks within the PRC. Cash in state-owned banks is covered by insurance up to RMB 500,000 ($72,500) per bank. The Company has not experienced any losses in such accounts and believes they are not exposed to any risks on its cash in these bank accounts.

During the three and six months ended June 30, 2023 and 2022, the Company had no customer that accounted for over 10% of its total revenue.

During the three months ended June 30, 2023, the Company had one supplier that accounted for 15% of its total purchases.

During the six months ended June 30, 2023, the Company had two suppliers that accounted for 15% and 13%, respectively, of its total purchases.

During the three months ended June 30, 2022, the Company had one supplier that accounted for 23% of its total purchases.

During the six months ended June 30, 2022, the Company had one supplier that accounted for 12% of its total purchases.

14

Leases

The Company determines if an arrangement is a lease at inception under FASB ASC Topic 842, Right of Use Assets (“ROU”) and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of its leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The ROU assets include adjustments for prepayments and accrued lease payments. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise such options.

ROU assets are reviewed for impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets.

ROU assets are tested for impairment individually or as part of an asset group if the cash flows related to the ROU asset are not independent from the cash flows of other major taxing jurisdictionsassets and liabilities. An asset group is the unit of accounting for long-lived assets to be held and used, which represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. The Company recognized no impairment of ROU assets as of June 30, 2023 and December 31, 2022. Operating leases are included in operating lease ROU and operating lease liabilities (current and non-current), on the consolidated balance sheets.

Statement of Cash Flows

In accordance with ASC Topic 230, “Statement of Cash Flows,” cash flows from the Company’s operations are calculated based on the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

Fair Value of Financial Instruments

The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, accrued liabilities and accounts payable, approximate their fair value due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the fair value of financial instruments held by the Company. The carrying amounts reported in the consolidated balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their fair value because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.

Fair Value Measurements and Disclosures

ASC Topic 820, “Fair Value Measurements and Disclosures,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels are defined as follow:

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

As of June 30, 2023 and December 31, 2022, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at fair value.

15

Foreign Currency Translation and Comprehensive Income (Loss)

The functional currency of the Company is subject.RMB. For financial reporting purposes, RMB is translated into USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet dates. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period.

 

Loss per ShareTranslation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive income”. Gains and losses resulting from foreign currency transactions are included in income. There was no significant fluctuation in the exchange rate for the conversion of RMB to USD after the balance sheet date.

 

The Company uses FASB ASC Topic 220, “Comprehensive Income”. Comprehensive loss is comprised of net loss and all changes to the statements of stockholders’ equity, except those due to investments by stockholders, changes in paid-in capital and distributions to stockholders. Comprehensive income (loss) for the three and six months ended June 30, 2023 and 2022 consisted of net income (loss) and foreign currency translation adjustments.

Earnings per Share

Basic lossincome (loss) per share wasis computed by dividingon the loss for each period applicable to the common shareholders bybasis of the weighted average number of common shares outstanding during the period. There

Dilution is computed by applying the treasury stock method for options and warrants. Under this method, options and warrants are no outstandingassumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock equivalents forat the six and three months ended November 30, 2017 or 2016 and they are thus not considered.average market price during the period.

 

ConcentrationAs of Credit RiskJune 30, 2023 and December 31, 2022, the Company did not have any potentially dilutive instruments.

 

The Company has no significant off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements.Stock-Based Compensation

 

Fair Value of Financial Instruments

The carrying value of cashCompany periodically grants stock options, warrants and accrued expenses, if applicable, approximate their fair valuesawards to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option, stock warrant and stock award grants to employees based on the short-term maturityauthoritative guidance provided by the FASB where the value of these instruments.the award is measured on the date of grant and recognized over the vesting period. The carrying amountsCompany accounts for stock option, stock warrant and stock award grants to non-employees in accordance with the authoritative guidance of debt were also estimatedthe FASB where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to approximate fair value.earn the equity instruments is complete. Stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the employees and non-employees, option, warrant and award grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

 

Segment Reporting

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The Company utilizes the methods of fair value (“FV”) measurement as described in ASC 820 to value its financial assets and liabilities. As defined in ASC 820, FVmanagement approach model is based on the price that would be received to sell an asset or paid to transferway a liability in an orderly transaction between market participants atcompany’s chief operating decision maker organizes segments within the measurement date. In order to increase consistencyCompany for making operating decisions assessing performance and comparability in FV measurements, ASC 820 establishes a FV hierarchy that prioritizes observable and unobservable inputs used to measure FV into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The FV hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices thatallocating resources. Reportable segments are based on inputs not quoted on active markets, but corroborated by market data.products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

 

Level 3: Unobservable inputsThe Company manages its business as four operating segments, products, pharmacies, hotel, and manufacture and sales, all of which are used when little or no market data is available. The FV hierarchy giveslocated in the lowest priority to Level 3 inputs.PRC. All of its revenues are derived in the PRC. All long-lived assets are located in PRC.

 

916

 

 

Related PartiesThe following table shows the Company’s operations by business segment for the three months ended June 30, 2023 and 2022.

SCHEDULE OF SEGMENTS INFORMATION

  2023  2022 
  For the Three Months Ended June 30, 
  2023  2022 
Net revenue        
Products $692,709  $16,591 
Pharmacies  305,186   194,045 
Hotel  390,530   210,251 
Manufacture and sale  87,632   - 
Total revenues, net $1,476,057  $420,887 
         
Operating costs and expenses        
Products        
Cost of goods sold $264,794  $3,735 
Operating expenses  460,255   362,220 
Pharmacies        
Cost of goods sold  181,875   150,263 
Operating expenses  57,198   153,842 
Hotel        
Hotel operating costs  462,780   418,100 
Operating expenses  53,245   71,965 
Manufacture and sale        
Cost of goods sold  4,531   - 
Operating expenses  96,147   - 
Total operating costs and expenses $1,580,825  $1,160,125 
         
Loss from operations        
Products $(32,340) $(349,364)
Pharmacies  66,113   (110,060)
Hotel  (125,495)  (279,814)
Manufacture and sale  (13,046)  - 
Loss from operations $(104,768) $(739,238)

17

The following table shows the Company’s operations by business segment for the six months ended June 30, 2023 and 2022.

 

The Company follows subtopic 850-10

  2023  2022 
  For the Six Months Ended June 30, 
  2023  2022 
Net revenue        
Products $855,969  $32,689 
Pharmacies  528,702   352,939 
Hotel  722,947   453,937 
Manufacture and sale  123,152   - 
Total revenues, net $2,230,770  $839,565 
         
Operating costs and expenses        
Products        
Cost of goods sold $299,528  $8,418 
Operating expenses  828,044   660,261 
Pharmacies        
Cost of goods sold  320,508   270,104 
Operating expenses  246,194   323,151 
Hotel        
Hotel operating costs  940,574   929,719 
Operating expenses  44,360   159,304 
Manufacture and sale        
Cost of goods sold  6,652   - 
Operating expenses  201,648   - 
Total operating costs and expenses $2,887,508  $2,350,957 
         
Loss from operations        
Products $(271,603) $(635,990)
Pharmacies  (38,000)  (240,316)
Hotel  (261,987)  (635,086)
Manufacture and sale  (85,148)  - 
Loss from operations $(656,738) $(1,511,392)

Segment assets As of
June 30, 2023
  As of
December 31, 2022
 
Products $358,219  $410,754 
Pharmacies  693,631   758,675 
Hotel  677,666   970,385 
Manufacture and sale  2,497,582   2,911,070 
Total assets $4,227,098  $5,050,884 

As the acquisition of Runcangsheng was consummated as of September 30, 2022 (see Note 17), the revenues and operating results of the FASB ASC for the identification of related partiesmanufacture and disclosure of related party transactions. Pursuant to Section 850-10-20 related parties include: a. affiliates of the Company; b. entities for which investmentssale segment were included in their equity securities would be required, absent the election of the FV option under the FV Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in those statements.

The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

Commitments and Contingencies

The Company follows subtopic 450-20 of the FASB ASC to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss toof the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment.beginning on October 1, 2022.

 

In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

18

New Accounting Pronouncements

 

If the assessment of a contingency indicates it is probable a material loss was incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.

New Accounting Pronouncements

In AugustJune 2016, the FASB issued ASU No. 2016-15, Classification2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies the presentation and classification of certain cash receipts and cash payments in the statement of cash flows.credit losses on financial assets measured at amortized cost. This ASUguidance is effective for public businessfiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017.2018. The Company does not anticipateis currently evaluating the impact that the adoption of this ASUstandard will have a significant impact on its consolidated financial statements.

In November 2016,January 2017, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash.2017-04, Simplifying the Test for Goodwill Impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its FV, not to exceed the carrying amount of goodwill. The guidance should be adopted on a prospective basis. As a smaller reporting company, the standard will be effective for the Company for interim and annual reporting periods beginning after December 15, 2022, with early adoption permitted. The adoption of ASU 2017-04 is not expected to have any impact on the Company’s consolidated financial statements presentation or disclosures.

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that a statementrequires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of cash flows explain the change during the periodcalculating diluted EPS when an instrument may be settled in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standardshares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2017, and2021 including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The standard should be applied using a retrospective transition method to each period presented. The Company does not anticipate the adoption of thisbut no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU will have a significant impact on its financial statements.

10

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard2020-06 is effective for fiscal years beginning after December 15, 2017,2023, including interim periods within those fiscal years. Early adoption is permitted. The standardEntities should be applied prospectively on or afteradopt the effective date. The Company will adopt this ASU for itsguidance as of the beginning of the fiscal year beginning January 1, 2018.of adoption and cannot adopt the guidance in an interim reporting period. The adoption of ASU 2020-06 is not expected to have any impact on the Company’s consolidated financial statements presentation or disclosures.

 

The Company has reviewed allCompany’s management does not believe that any other recently issued, but not yet effective, accounting pronouncements and have determined that these new accounting pronouncements are either not applicable orauthoritative guidance, if currently adopted, would not have a material impact on the results of operationsCompany’s financial statement presentation or changes in the financial position.disclosures.

NOTE 2 - RELATED PARTY TRANSACTIONS

As of November 30, 2017, the Company had due to related parties of $248,265, of which, 1) $164,877 was due to China Concentric as a result of an assignment of rights to advances previously made by Algodon, the Company’s former parent. The assignment of rights was made concurrent with the sale by Algodon of its shares in the Company to China Concentric on January 20, 2017. This advance carries no interest. 2) $1,800 advanced to the Company for paying certain company’s expenses by Mr. Zhu, a shareholder of the Company. 3) $81,588 advanced to the Company for paying G&A expenses by an officer of the Company.

As of May 31, 2017, the Company had 1) advances due China Concentric of $164,877. This total advance, which was assigned to China Concentric by Algodon, carries no interest. 2) $1,800 advanced to the Company for paying certain Company expenses by Mr. Zhu, a shareholder of the Company.

NOTE 3 - INCOME TAXES

As of November 30, 2017, the Company had a net operating loss (“NOL”) carry-forward for income tax reporting purposes of approximately $451,915 that may be offset against future taxable income through 2036. Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs. Therefore, the amount available to offset future taxable income may be limited. No tax benefit has been reported in the financial statements, because the Company believes there is a 50% or greater chance that the realization of the Company’s net deferred tax assets resulting from NOL carry-forwards will expire unused. Accordingly, the potential tax benefits of the loss carry-forwards are offset by a valuation allowance of the same amount.

Components of deferred tax assets are as follows:

  November 30, 2017  May 31, 2017 
Expected income tax benefit from NOL carry-forwards $141,671  $123,180 
Less: valuation Allowance  (141,671)  (123,180)
Net deferred tax assets – Non-current: $-  $- 

 

1119

 

 

3. OTHER RECEIVABLES AND PREPAID EXPENSES

Other receivables and prepaid expenses consisted of the following at June 30, 2023 and December 31, 2022:

SCHEDULE OF OTHER RECEIVABLES AND PREPAID EXPENSES

  June 30, 2023  December 31, 2022 
Deposits $12,320  $15,546 
Prepaid expenses  19,768   9,490 
Employees’ social insurance  9,904   10,124 
Others  24,339   7,471 
Total $66,331  $42,631 

4. ADVANCES TO SUPPLIERS

The provisionCompany had advances to suppliers of $156,745 and $168,523 as of June 30, 2023 and December 31, 2022, respectively. Advances to suppliers primarily include prepayments for income taxes differs fromproducts expected to be delivered subsequent to balance sheet dates.

5. INVENTORIES

Inventories consisted of the amount computed usingfollowing at June 30, 2023 and December 31, 2022:

SCHEDULE OF INVENTORIES

  June 30, 2023  December 31, 2022 
Raw material $142,571  $62,462 
Work in process  2,742   15,315 
Finished goods-health supplements  -   521 
Drugs, pharmaceutical and nutritional products  491,936   412,129 
Food and beverage, hotel supplies and consumables  70,211   82,646 
Total $707,460  $573,073 
Less: reserve for inventory  81,708   73,821 
Total inventories, net $625,752  $499,252 

6. PROPERTY AND EQUIPMENT, NET

Property and equipment consisted of the federal US statutory income tax ratefollowing at June 30, 2023 and December 31, 2022:

SCHEDULE OF PROPERTY AND EQUIPMENT

  June 30, 2023  December 31, 2022 
Vehicles $405,993  $426,836 
Office furniture  78,518   82,549 
Electronic equipment  21,231   20,607 
Machinery  1,184,382   1,241,778 
Leasehold improvements  1,083,462   1,139,087 
Other  21,914   17,485 
Total  2,795,500   2,928,342 
Less: Accumulated depreciation  (1,094,193)  (956,549)
Property and equipment, net $1,701,307  $1,971,793 

Depreciation expense for the three months ended June 30, 2023 and 2022 was $88,509 and $26,947, respectively.

Depreciation expense for the six months ended NovemberJune 30, 20172023 and 2016 is as follows:2022 was $192,909 and $55,925, respectively

20

7. INTANGIBLE ASSET, NET

 

Intangible asset consisted of the following at June 30, 2023 and December 31, 2022:

  2017  2016 
Provision (Benefit) at US Statutory Rate $(18,491) $(7,095)
Increase (Decrease) in Valuation Allowance  18,491   7,095 
  $-  $- 

SCHEDULE OF INTANGIBLE ASSET

  June 30, 2023  December 31, 2022 
Software $10,675  $8,564 
Less: Accumulated amortization  (7,434)  (7,295)
Intangible asset, net $3,241  $1,269 

 

The provision for income taxes differs from the amount computed using the federal US statutory income tax rateAmortization expense for the three months ended NovemberJune 30, 20172023 and 2016 is as follows2022 was $357 and $633, respectively.

 

  2017  2016 
Provision (Benefit) at US Statutory Rate $(6,970) $(4,063)
Increase (Decrease) in Valuation Allowance  6,970   4,063 
  $-  $- 

The Company evaluates its valuation allowance requirements based on projected future operations. When circumstances changeAmortization expense for the six months ended June 30, 2023 and cause a change in management’s judgment about the recoverability of deferred tax assets, the impact of the change on the valuation is reflected in current income.2022 was $518 and $1,294, respectively.

 

NOTE 4 – CHANGE IN CONTROL8. TAXES PAYABLE

 

On January 20, 2017, Algodon Wines & Luxury Development Group, Inc. (“Algodon”), the owner of at least 43,822,001 shares (the “Algodon Shares”), or 96.5%Taxes payable consisted of the outstanding common stockfollowing at June 30, 2023 and December 31, 2022:

SCHEDULE OF TAX PAYABLE

  June 30, 2023  December 31, 2022 
Value-added $57,316  $56,806 
Income  29,409   30,919 
City construction  4,148   3,746 
Education  2,966   2,184 
Other  9,797   10,445 
Taxes payable $103,636  $104,100 

9. ACCRUED LIABILITIES AND OTHER PAYABLES

Accrued liabilities and other payables consisted of the following at June 30, 2023 and December 31, 2022:

SCHEDULE OF ACCRUED LIABILITIES AND OTHER PAYABLES

  June 30, 2023  December 31, 2022 
Accrued employees’ social insurance $250,302  $270,349 
Accrued payroll and commission  347,562   307,331 
Accrued rent expense  49,916   32,746 
Construction payable  1,217,754   1,384,674 
Payable for equipment purchase  23,689   32,278 
Accrued professional fees  194,393   233,894 
Deposit  11,084   11,308 
Other payables  48,731   83,910 
Total $2,143,431  $2,356,490 

21

10. LOAN FROM THIRD PARTIES

As of June 30, 2023 and December 31, 2022, the Company sold the Algodon Shareshad advances from unrelated third parties of Aixin Shangyan Hotel in an aggregate amount $82,744 and $86,992, respectively. There was no written agreement, and these loans are payable on demand and bear no interest.

11. LEASE

AiXinZhonghong leases its office on a monthly basis. AiXinZhonghong also has operating leases for other sales locations under various operating lease arrangements. The leases have remaining lease terms of approximately 0.25 to China Concentric Capital Group Ltd.,4.92 years.

Aixin Shangyan Hotel leases its hotel premises under an operating lease arrangement. The lease has a British Virgin Islands company (“China Concentric”), for $260,000 pursuantremaining lease term of approximately 0.50 years.

Aixintang Pharmacies lease retail pharmacy stores under operating lease arrangements, with remaining lease terms of 1.46 to 3.17 years.

Runcangsheng leases its office under an operating lease arrangement. The lease has a Stock Purchase Agreement dated December 20, 2016, as amended. Algodon also assigned to China Concentric all its right, title and interest to amounts payable to Algodon for non-interest bearing advancesremaining lease term of approximately 2.67 years.

Balance sheet information related to the Company, which advances,Company’s leases is presented below:

SCHEDULE OF OPERATING LEASE LIABILITIES

  June 30, 2023  December 31, 2022 
Operating Leases        
Operating lease right-of-use assets $682,694  $999,285 
         
Operating lease liabilities – current $601,626  $883,583 
Operating lease liability – non-current  205,903   194,725 
Total operating lease liabilities $807,529  $1,078,308 

The following provides details of the Company’s lease expenses:

SCHEDULE OF OPERATING LEASE EXPENSES

  2023  2022 
  Three Months Ended June 30, 
  2023  2022 
Operating lease expenses $207,035  $220,203 

  2023  2022 
  Six Months Ended June 30, 
  2023  2022 
Operating lease expenses $417,369  $449,445 

Other information related to leases is presented below:

SCHEDULE OF OTHER INFORMATION RELATED LEASES

  Six Months Ended June 30, 
  2023  2022 
Cash Paid for Amounts Included In Measurement of Liabilities:        
Operating cash flows from operating leases $405,079   418,711 
         
Weighted Average Remaining Lease Term:        
Operating leases  1.46 years   1.91 years 
         
Weighted Average Discount Rate:        
Operating leases  4.75%  4.75%

22

Maturities of lease liabilities were as follows:

SCHEDULE OF MATURITIES OF LEASE LIABILITIES

     
For the year ending December 31:    
2023 (excluding the six months ended June 30, 2023) $543,223 
2024  150,094 
2025  88,611 
2026  37,969 
2027  8,274 
Thereafter  3,448 
Total lease payments  831,619 
Less: imputed interest  (24,090)
Total lease liabilities  807,529 
Less: current portion  (601,626)
Lease liabilities – non-current portion $205,903 

12. RELATED PARTY TRANSACTIONS

SCHEDULE OF ADVANCES AND ACCOUNTS PAYABLE TO RELATED PARTY

Advances to supplier – related party

Advances to supplier – related party consisted of the following as of January 20, 2017 were $164,877.the periods indicated:

  June 30, 2023  December 31, 2022 
Chengdu Aixin International Travel Service Co., Ltd $25,453  $     - 

Accounts payable – related party

Accounts payable – related party consisted of the following as of the periods indicated:

  June 30, 2023  December 31, 2022 
Luquan Shengcaofeng Biotechnology Co., Ltd. $-  $165,958 

Luquan Shengcaofeng Biotechnology Co., Ltd. is an entity controlled by Mr. Huiliang Jiao, a Director of the Company.

 

On February 2, 2017, China Concentric soldDue from related parties

Due from related parties consisted of the following as of the periods indicated:

SCHEDULE OF RELATED PARTY TRANSACTIONS

  June 30, 2023  December 31, 2022 
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd. $4,925  $9,708 
Sichuan Aixin Investment Co., Ltd  8,978   145 
Chengdu Fuxiang Tang Pharmacy Co., Ltd.  27,302   26,125 
Chengdu WenJiang Aixin Huiwan Pharmacy Co., Ltd.  459   - 
Chengdu Xilongwan Pharmacy Co., Ltd.  414   - 
Chengdu Heshengyuan Pharmacy Co., Ltd.  2,069   - 
Chengdu Zhiweibing Pharmacy Co., Ltd.  4,156   - 
Chengdu Tongtai Tang Pharmacy Co. Ltd.  1,089   - 
Chengdu city Wuhou District Xiaofei Pharmacy Co., Ltd  4,982   - 
Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd  26,126   34,622 
Chengdu Cigu Foshou Pharmacy  1,514   - 
Mianyang Aixin Cunshan Pharmacy  1,540   - 
Chengdu Aixin International Travel Service Co., Ltd  359     
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.  50,407   12,502 
Total $134,320  $83,102 
Advance from related parties $134,320  $83,102 

Due to related parties

Due to related parties consisted of the following as of the periods indicated:

  June 30, 2023  December 31, 2022 
Quanzhong Lin $109,354  $140,644 
Yirong Shen  85,502   89,892 
Tianming Long  1,040   - 
Sichuan Yunxi Pharmacy Co. Ltd  1,931   - 
Chengdu Yi Yan Tang Pharmacy Co. Ltd.  1,635   - 
Chengdu Aixin International travel service Co, Ltd  4,981   6,346 
Total $204,443  $236,882 
Advance to related parties $204,443  $236,882 

The amouints due to and from related parties were for working capital purposes, payable on demand, and bear no interest. All the related party entities listed above are controlled by Mr. Quanzhong Lin (the Chairman, President and major shareholder of Aixin Life). Yirong Shen was a major shareholder of Aixin Shangyan Hotel prior to the closing of Hotel Purchase Agreement, and she serves as the supervisor of Aixin Shangyan Hotel. Tianming Long is a branch manager of Aixintang Pharmacies.

23

Office leases

In May 2014, the Company entered a lease with its major shareholder for an entrepreneur residentoffice. The lease term was for three years expiring in May 2017 with an option to renew. The monthly rent was RMB 5,000 ($690). The Company was required to prepay each year’s annual rent at 15th of May of each year. The Company renewed the lease until May 28, 2028with monthly rent of RMB 5,000 ($690), payable quarterly. The future annual minimum lease payments at June 30, 2023 are $8,274, $8,274, $8,274, $8,274, and $7,585 for each of the years ended June 30, 2024, 2025, 2026, 2027, and 2028, respectively.

Runcangsheng has an office lease with Xiaoyan Zhou, wife of Huiliang Jiao, the Company’s Director, from March 2020 to February 2023 with a monthly rent of RMB 3,000 ($414). Runcangsheng renewed the lease until February 28, 2026 with monthly rent of RMB 5,000 ($690). The future annual minimum lease payments at June 30, 2023 are $8,274, $8,274, and $5,516 for each of the years ended June 30, 2024, 2025, and 2026, respectively.

13. INCOME TAXES

The Company was incorporated in the People’s RepublicUnited States of America (“USA”) and has operations in one tax jurisdiction, i.e. the PRC. The Company generated substantially all of its sales from its operations in the PRC for the three and six months ended June 30, 2023 and 2022, and recorded income tax provision for the periods.

China 29,521,410has a tax rate of 25% for all enterprises (including foreign-invested enterprises).

Uncertain Tax Positions

Interest associated with unrecognized tax benefits are classified as income tax, and penalties are classified in selling, general and administrative expenses in the statements of operations. For the six and three months ended June 30, 2023 and 2022, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

14. STOCKHOLDERS’ EQUITY

On August 17, 2020, by unanimous written consent in lieu of a meeting, the Board adopted resolutions authorizing a one (1)-for-four (4) reverse stock. The reverse stock split became effective on October 27, 2020. According to the Articles of Amendment, the Company is authorized to issue 20,000,000shares it purchased from Algodon, approximately 65%of blank check preferred stock at $0.001 par value and 500,000,000 shares of common stock at $.00001 par value per share.

Pursuant to resolutions adopted by the Board of Directors and the holders of a majority of the outstanding shares of the Company’s common stock for $300,000, pursuantof AiXin Life International, Inc. on January 6, 2023, the Company filed an amendment to its Articles of Incorporation with respect to a Stock Purchase Agreement dated December 21, 2016.proposed 1 for 2 “reverse” split of its common stock (the “Amendment”). Completion of the proposed reverse stock split was to be effected on a date determined by the Board of Directors only upon receipt of notice from the Financial Industry Regulatory Authority (“FINRA”) that it would process the proposed reverse stock split. The Company received notice from FINRA and its common stock began trading on a post-split basis on February 17, 2023.

 

Mr. Lin indicated he is purchasingAs a controlling interest inresult of the reverse split, every two shares of the Company’s issued and outstanding common stock were automatically combined and converted into one issued and outstanding share of common stock. The Company withhas approximately 24,999,842 shares of outstanding common stock after giving effect to the intentionreverse stock split and the elimination of acquiring an operating business in a reverse acquisition transaction through a share exchange. There can be no assurance that an acquisition of any particular business will be consummated.fractional shares.

 

All share and earnings per share information has been retroactively adjusted to reflect the reverse stock split.

As of June 30, 2023, and December 31, 2022, the Company had 24,999,842 common shares issued and outstanding.

Stock Awards Issued for Services

On October 22, 2019, the Company granted and issued 18,750 shares to its employees and contractors under its 2019 Equity Incentive Plan. The stock awards were valued at $337,500 based on the post-split closing price of $18 on the grant date.

24

On October 24, 2019, the Company granted and issued 275,000 shares to its employees and contractors under its 2019 Equity Incentive Plan. The stock awards were valued at $1,520,200 based on the post-split closing price of $5.528 on the grant date.

The stock awards will vest over five (5) years from the grant date, and the grantee will forfeit a portion of the shares granted (“Shares Granted”) if the grantee is no longer employed by or contracted with the Company. Specifically, the grantee will forfeit 80% of Shares Granted if no longer employed by or contracted with the Company on the date that is one year from the grant date, forfeit 60% of Shares Granted if no longer employed by or contracted with the Company on the date that is two years from the grant date, forfeit 40% of Shares Granted if no longer employed by or contracted with the Company on the date that is three years from the grant date, and forfeit 20% of Shares Granted if no longer employed by or contracted with the Company on the date that is four years from the grant date. Effective on the 5th year from the grant date, none of the shares will be subject to forfeiture.

For the three months ended June 30, 2023 and 2022, stock-based compensation expenses were $92,885 and $92,885, respectively. For the six months ended June 30, 2023 and 2022, stock-based compensation expenses were $185,770 and $185,770, respectively. As of June 30, 2023, unrecognized compensation expenses related to these stock awards are $486,897. These expenses are expected to be recognized over 1.32 years.

Capital Contribution

During the six months ended June 30, 2023, the Company received capital contributions in the aggregate amount of $145,300 from Yunnan Shengshengyuan and Yun Chen, the former shareholders of Runcangsheng (see Note 1), who remained as related parties of the Company after the completion of acquisition of Runcangsheng.

15. STATUTORY RESERVES

Pursuant to the PRC corporate law, the Company is now only required to maintain one statutory reserve by appropriating from its after-tax profit before declaration or payment of dividends. The statutory reserve represents restricted retained earnings.

Surplus reserve fund

The Company is required to transfer 10% of its net income, as determined under PRC accounting rules and regulations, to a statutory surplus reserve fund until such reserve balance reaches 50% of the Company’s registered capital. During the three and six months ended June 30, 2023 and 2022, the Company make $0 and $0 contribution to statutory reserve fund.

The surplus reserve fund is non-distributable other than during liquidation and can be used to fund previous years’ losses, if any, and may be utilized for business expansion or converted into share capital by issuing new shares to existing shareholders in proportion to their shareholding or by increasing the par value of the shares currently held by them, provided that the remaining reserve balance after such issue is not less than 25% of the registered capital.

Common welfare fund

Common welfare fund is a voluntary fund to which the Company can elect to transfer 5% to 10% of its net income, as determined under PRC accounting rules and regulations. The Company did not make any contribution to this fund during the three and six months ended June 30, 2023 and 2022.

This fund can only be utilized on capital items for the collective benefit of the Company’s employees, such as construction of dormitories, cafeteria facilities, and other staff welfare facilities. This fund is non-distributable other than upon liquidation.

16. OPERATING CONTINGENCIES

The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

The Company’s sales, purchases and expenses are denominated in RMB and all of the Company’s assets and liabilities are also denominated in RMB. The RMB is not freely convertible into foreign currencies under the current law. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain supporting documentation to affect the remittance.

25

Litigation

The Company is, from time to time, involved in litigation incidental to the conduct of its business regarding merchandise sold, employment matters, and litigation regarding intellectual property rights.

In December 2020, Jian Yiao (the “Plaintiff”) filed a complaint against Chengdu Aixintang Pharmacy Co., Ltd. (“Aixintang Pharmacy”, or the “Defendant”) in Zhangjiagang People’s Court in Jiangsu Province. The complaint alleges that Jian Yiao is entitled to $392,305 (RMB 2,500,000) from Aixintang Pharmacy for not fulfilling the contractual obligation of a purchase agreement entered in March 2020 (the “Purchase Agreement”). Aixintang Pharmacy claimed that the Purchase Agreement was falsely entered by an employee through forged documents, and that Aixintang Pharmacy did not enter the Purchase Agreement. The Court determined that Aixintang Pharmacy breached the Purchase Agreement by not delivering the products ordered and ordered Aixintang Pharmacy to pay $392,305 (RMB 2,500,000) to the Plaintiff. In December 2020, Aixintang Pharmacy filed a motion in the Jiangsu Suzhou Intermediate People’s Court against the determination reached from the first trial.

In February 2021, the judge in the Jiangsu Suzhou Intermediate People’s Court denied the Defendant’s motion and upheld the judgment from the first trial. In March 2021, Aixintang Pharmacy filed another motion to the Jiangsu High People’s Court on the basis that the Purchase Agreement was forged. In February 2022, Aixintang Pharmacy filed an appeal in Jiangsu High People’s Court against the judgment reached by Jiangsu Suzhou Intermediate People’s Court in February 2021. To date, this legal proceeding remains pending.

In November 2021, the Company and Mr. Quanzhong Lin agreed that Mr. Lin shall assume any losses arising from this legal proceeding. As such, the Company did not accrue contingent losses from this legal proceeding as of June 30, 2023.

The Company believes that current pending litigation will not have a material adverse effect on its consolidated financial position, results of operations or cash flows.

17. ACQUISITION OF SUBSIDIARIES

Runcangsheng

On July 21, 2017,19, 2022, the Company entered into an Equity Transfer Agreement with Yunnan Shengshengyuan Technology Co., Ltd (“Shengshengyuan”) and PlanYun Chen (collectively “the Sellers”), who own 95% and 5% equity interest of Merger pursuant to whichYunnan Runcangsheng Technology Co., Ltd (“Runcangsheng”), respectively.

Under the terms of the Transfer Agreement, the Company would be merged withpurchased all of the outstanding equity interest of Yunnan Runcangsheng for an aggregate purchase price of RMB 31,557,820, or $4,418,095, adjusted by $116,802, the amount equal to the initial net worth estimate minus the audited net worth of Runcangsheng as of December 31, 2021.

In addition to transferring their respective equity interest in Runcangsheng, both Sellers agreed to forgive any loans due to them from Runcangsheng. The acquisition was completed on September 30, 2022.

The following table summarizes the fair values of the assets acquired and into a newly-formed wholly-owned subsidiary, AiXin Life International, Inc., a Nevada corporation,liabilities assumed at the date of acquisition. Goodwill as a result of which the Company’s stateacquisition of incorporation would be changed from Colorado to Nevada. The Merger was subject to approval by the Financial Regulatory Authority. On August 25, 2017, the Company terminated the Agreement and Plan of Merger with its newly-formed wholly-owned subsidiary, AiXin Life International, Inc.,Runcangsheng is calculated as a result of which it would have become a Nevada corporation.follows:

SCHEDULE OF FAIR VALUES OF THE ASSETS ACQUIRED AND LIABILITIES ASSUMED 

NOTE 5 – SUBSEQUENT EVENT

On December 12, 2017, the Company entered into and closed a share exchange agreement, with AiXin (BVI) International Group Co., Ltd. a British Virgin Islands corporation (“AiXin BVI”), and Quanzhong Lin, the sole stockholder of AiXin BVI (the “AiXin BVI Stockholder”), pursuant to which the Company acquired 100% of the outstanding capital stock of AiXin BVI for 227,352,604 shares of the Company’s common stock (the “Share Exchange” or the “AiXin Acquisition”). After giving effect to the Share Exchange, the Company had outstanding 317,988,089 shares of common stock.

     
Total purchase considerations $4,301,293 
Estimated fair value of assets acquired:    
Cash $446,381 
Accounts receivable  144,813 
Accounts receivable-related party  133,011 
Advance to suppliers  3,455 
Other receivables and prepaid expense  127,909 
Inventory  469,594 
Property and equipment  1,677,272 
Intangible assets  1,406 
Operating lease right-of-use assets  1,990 
Total assets acquired  3,005,831 
Estimated fair value of liabilities assumed:    
Accounts payable  (89,801)
Accounts payable-related party  (160,911)
Advance from customers  (4,790)
Government grant  (921,473)
Taxes payable  (21,156)
Operating lease liability  (15,182)
Accrued liabilities and other payables  (1,314,995)
Total liabilities assumed  (2,528,308)
Total net assets acquired  477,523 
Goodwill as a result of the acquisition $3,823,770 

 

1226

 

During the year ended December 31, 2022, the Company recorded a goodwill impairment equal to the goodwill resulting from the acquisition of Runcangsheng.

 

As a resultThe following condensed unaudited pro forma consolidated results of operations for the Company, Runcangsheng, Aixin Shangyan Hotel and Aixintang Pharmacies for the three and six months ended June 30, 2022 present the results of operations of the Share Exchange, AiXin BVI becameCompany, Runcangsheng, Aixin Shangyan Hotel, and Aixintang Pharmacies as if the Company’s wholly-owned subsidiary,acquisition of Runcangsheng occurred on January 1, 2022, respectively.

The pro forma results are not necessarily indicative of the actual results that would have occurred had the acquisition been completed as of the beginning of the periods presented, nor are they necessarily indicative of future consolidated results.

SCHEDULE OF BUSINESS ACQUISITION PRO FORMA

  

For the

Three Months Ended

June 30, 2022

 
Revenue $548,308 
Operating costs and expenses  1,336,027 
Loss from operations  (787,719)
Other income  30,167 
Income tax expense  473 
Net loss $(758,025)

  

For the

Six Months Ended

June 30, 2022

 
Revenue $1,050,147 
Operating costs and expenses  2,620,971 
Loss from operations  (1,570,824)
Other income  50,768 
Income tax expense  965 
Net loss $(1,521,021)

18. SUBSEQUENT EVENT

The Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through the date the financial statements were issued and determined the Company now owns all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”), which in turn owns all of the outstanding shares of Chengdu AiXin Zhonghong Biological Technology Co., Ltd., a Chinese limited company (“AiXin Zhonghong”), which markets and sells innovative, premium-quality nutritional products in Chengdu, China.has no material subsequent events.

 

27

AiXin BVI was incorporated on September 21, 2017 to serve as a holding company and AiXin HK was established in Hong Kong on February 25, 2016 to serve as an intermediate holding company. AiXin Zhonghong was established in the PRC on March 4, 2013, and on June 1, 2017 the local government of the PRC issued a certificate of approval regarding the foreign ownership of AiXin Zhonghong by AiXin HK. Neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017.

 

Prior to the AiXin Acquisition, Quanzhong Lin, the Company’s President and Chief Executive Officer, owned all of the outstanding shares of AiXin BVI and 29,521,410 shares of the Company’s common stock, approximately 65% of the outstanding shares of the Company. As a result of the Share Exchange, Mr. Lin now owns 256,874,014 shares of the Company’s common stock, approximately 80.78% of the Company’s outstanding shares.

For accounting purposes, the acquisition was accounted for as a reverse acquisition and was treated as a recapitalization of Mercari Communications Group, Ltd. effected by a share exchange, with AiXin BVI as the accounting acquirer. Since neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017, the historical financial statements of AiXin Zhonghong are now the historical financial statements of the registrant, Mercari Communications Group, Ltd. The assets and liabilities of AiXin Zhonghong have been brought forward at their book value and no goodwill has been recognized.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

General

The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited financial statements and the notes to those statements included elsewhere in this Form 10-Q and with the audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended MayDecember 31, 20172022 (the “2017“2022 Form 10-K”). This discussion contains forward-looking statements that involve risks and uncertainties. You should specifically consider the various risk factors identified in our 20172022 Form 10-K, that could cause actual results to differ materially from those anticipated in these forward-looking statements.

Plan of OperationsOverview

UntilIn December 12, 2017, we werecompleted a “shell company” (as that term is defined in Rule 12b-2 under“reverse” acquisition whereby we acquired all of the Exchange Act) because we had no or nominal assets (other than cash) and no or nominal operations. On December 12, 2017, we acquiredoutstanding shares of AiXin (BVI) International Group Co., Ltd. a British Virgin Islands corporation (“AiXin BVI”), for 227,352,604 shares of our common stock (the “Share Exchange”). As a result, of the Share Exchange, AiXin BVI became our wholly-owned subsidiary, and through AiXin BVI we now own all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”), which in turn owns all of the outstanding shares of Chengdu AiXin ZhonghongAiXinZhonghong Biological Technology Co., Ltd., a Chinese limited company (“AiXin Zhonghong”AiXinZhonghong”), which markets and sells innovative, premium-qualitybegan distributing nutritional products in 2013.

In September 2021, we completed the acquisition of nine pharmacies located in Chengdu China. For information concerningby acquiring the businessentities which owned the pharmacies for an aggregate purchase price of AiXin Zhonghong, including financial informationRMB 34,635,845, or approximately US$5.31 million. Since that time, the number of our pharmacies has increased to 13.

Pursuant to an Equity Transfer Agreement (the “Transfer Agreement”), on September 30, 2022, we acquired all of the outstanding equity of Yunnan Runcansheng Technology Co., Ltd (“Runcansheng”) for RMB 31,557,820 (approximately USD$4.4 million), reduced by $116,802 the years endedexcess of the estimated net worth of Runcangsheng over its audited net worth as of December 31, 20162021. In addition to transferring their respective equity interest in Runcangsheng, both Sellers agreed to forgive any loans due to them from Runcangsheng. Runcangsheng operates a 13,000 square meter production facility, which houses R&D centers, extraction facilities, preparation workshops and 2015,a warehouse. Runcangsheng has more than 30 sub brands and operates planting facilities where it grows some of the key ingredients used in its products. Many of the products it has developed are specifically targeted to alleviate symptoms associated with the increasingly competitive and pressured lifestyle of the Chinese middle class.

Runcangsheng. was established in April 2020, and is headquartered in Luquan Yi and Miao Autonomous County, Kunming City, Yunnan Province. It is focused on promoting a healthy lifestyle through the use of foods believed to promote well-being, health foods, modernized versions of traditional Chinese medical products and plant extracts. Runcangsheng cultivates many of the raw materials used in its products, compounds the materials into easy to transport and use pre-packaged foods and distributes the products at the wholesale level. As life-styles in China evolve, work pressures increase and the nine monthsingestion of meats and other western style foods increases, Runcangsheng seeks to design and market products intended to combat the increase in obesity, hypertension, insomnia and physical ailments associated with such changes. The acquisition of Runcangsheng will enable us to operate as a vertically integrated company, capable of formulating the kinds of health foods and other nutritional products and supplements suitable for our clients and marketing those products through our distribution channels.

In addition to our acquisitions in the health and nutritional sector, in July 2021, we completed the acquisition of Aixin Shangyan Hotel which owns and operates a hotel located in the Jinniu District, Chengdu City. The hotel covers more than 8,000 square meters and has a large restaurant that can accommodate 600 people, 6 luxury dining rooms, a 200 square meter music tea house, 13 private tea rooms, 108 guest rooms and other supporting facilities. We acquired the hotel through an acquisition of the outstanding equity of Aixin Shangyan Hotel for a purchase price of RMB 7,598,887, or approximately $1.16 million. We envision utilizing the hotel to conduct marketing events and seminars for our customers, and training sessions for our personnel at which we introduce new products and services intended to promote healthy living.

We intend to look for additional opportunities to profit from the growing healthcare market in China. Though currently we are not party to any agreements, we will explore, among other opportunities, expanding our product line through internal research and acquiring complementary products from third parties, acquiring additional pharmacies and other retail outlets and operating nursing homes and possibly clinics which provide medical care to clients.

28

Our Business

We are focused on providing health and wellness products to the growing middle class in China. We currently develop, manufacture, market and sell premium-quality healthcare, nutritional products and wellness supplements, including herbs and greens, traditional Chinese remedies, functional products, such as weight management tools, probiotics, foods and drinks. We also offer products purchased from third parties and provide advertising and marketing services to clients which engage us to market and distribute their products. We offer our products and those of clients for which we provide marketing services, through a diversified, omni-channel business model which generates revenues through retail and wholesale product sales, through company-owned pharmacies, direct marketing and e-commerce. Our marketing approach emphasizes proactively approaching customers such as by hosting marketing events for clients, which we believe is ideally suited to marketing the products we offer because sales of healthcare, nutritional products and supplements are strengthened by ongoing personal contact and support, coaching and education among the Company and our clients towards how to achieve a healthy and active lifestyle.

We believe the competitive strengths that will enable us to grow in the health and wellness market include our ability to design and manufacture products that are responsive to consumers’ needs as the life style of China’s middle class evolves, our coordinated omni-channel distribution network where we enable consumers to obtain the information they need to improve their lifestyle on our website, at our pharmacies and through individual meetings with our team members.

Our ability to operate profitably and generate positive cash flow will be determined by our ability to attract a large and loyal customer base and provide the information and products they need cost effectively. Our revenue will largely be determined by our ability to achieve and maintain a strong brand name and company image, the volume of products we sell and the prices we can charge for such products, which will require that we compete effectively. Our costs will largely be determined by the cost of raw materials and acquired inventory, the labor used to design and manufacture products, and the costs incurred to deliver these products to the consumer.

In March 2020, the World Health Organization announced that infections caused by the coronavirus disease of 2019 (“COVID-19”) had become pandemic and national, provincial and local authorities in China, including those whose jurisdictions include Chengdu, where our offices, hotel and pharmacies are located, adopted various regulations and orders, including “shelter in place” rules, restrictions on travel, mandates on the number of people that may gather in one location and closing non-essential businesses. Due to China’s enforcement of its zero-tolerance policy, Chengdu had been subject to shelter in place rules, lockdowns, restrictions on travel and other measures which negatively impacted our business operations. In particular, lockdowns, limitations on travel and limits on the number of people that may gather in one location negatively impacted our marketing efforts. China recently moved away from its reliance upon a “zero-tolerance” policy and suspended all Covid restrictions and it has been reported that the number of COVID-19 cases in China has surged after the government abandoned its zero-tolerance policy. It is likely that this sudden increase in COVID cases caused many individuals to voluntarily restrict their travel in the beginning of 2023 which could adversely impact many industries in China, including ours. Moreover, the perception that Covid-19 and other infectious diseases are on the rise, may make some potential customers reluctant to attend large gatherings or meet with members of our sales team which could limit our sales growth. We have implemented procedures to promote employee and customer safety. These measures do not significantly increase our operating costs.

We intend to build a reputation as a provider of premium health and wellness products that seeks to improve our customers health and well-being. Our objective is to offer a broad and deep mix of products for consumers interested in living well, whether they are looking to treat a health-related issue or simply maintain their overall wellness, Our premium, value-added offerings include both proprietary products developed and manufactured by us as well as products acquired from or sold on behalf of third parties. We believe our range of products and ability to develop new products, combined with the customer support and service we offer, differentiate us and allow us to effectively compete against food, drug and mass channel players, specialty stores, independent vitamin, supplement and natural food shops and online retailers. There is no assurance that we will achieve our business objectives.

29

Results of Operations

Three Months ended SeptemberJune 30, 2017, see our Current Report on Form 8-K filed on December 14, 2017 (the “Form 8-K”).2023 and 2022

The financial information contained herein reflects our financial position andfollowing table sets forth the results of our operations priorfor the periods indicated as a percentage of net revenue, certain columns may not add due to rounding:

  Three Months Ended June 30, 
  2023  2022 
  $  

% of

Revenue

  $  

% of

Revenue

 
Revenue $1,476,057   100% $420,887   100%
Operating costs and expenses  1,580,825   107%  1,160,125   276%
Income (loss) from operations  (104,768)  (7)%  (739,238)  (176)%
Non-operating income, net  12,129   1%  11,442   3%
Loss before income tax  (92,639)  (7)%  (727,796)  (173)%
Income tax expense  4,907   -%  473   0.1%
Net loss $(97,546)  (7)% $(728,269)  (173)%

The following table shows our operations by business segment for the consummation ofthree months ended June 30, 2023 and 2022. Because Runcangsheng was acquired in September 2022, it did not contribute to our financial results for the Share Exchange and does not reflect the current status of our operations. For information regarding our current business activities, please refer to the Form 8-K filed December 14, 2017.three months ended June 30, 2022.

  For the Three Months Ended June 30, 
  2023  2022 
Net revenue        
Products $692,709  $16,591 
Pharmacies  305,186   194,045 
Hotel  390,530   210,251 
Manufacture and sale  87,632   - 
Total revenues, net $1,476,057  $420,887 
         
Operating costs and expenses        
Products        
Cost of goods sold $264,794  $3,735 
Operating expenses  460,255   362,220 
Pharmacies        
Cost of goods sold  181,875   150,263 
Operating expenses  57,198   153,842 
Hotel        
Hotel operating costs  462,780   418,100 
Operating expenses  53,245   71,965 
Manufacture and sale        
Cost of goods sold  4,531   - 
Operating expense  96,147   - 
Total operating costs and expenses $1,580,825  $1,160,125 
         
Loss from operations        
Products $(32,340) $(349,364)
Pharmacies  66,113   (110,060)
Hotel  (125,495)  (279,814)
Manufacture and sale  (13,046)  - 
Loss from operations $(104,768) $(739,238)

1330

 

Revenue

Results of Operations

We did not have any revenues duringRevenue was $1,476,057 in the six and three months ended NovemberJune 30, 2017.2023, compared to $420,887 in the same period of 2022, an increase of $1,055,170 or 251%. The increase in revenue was mainly due to increases in direct sales of our nutritional products, increases in revenues from our hotel and pharmacies, and the generation of revenue from the manufacture and sale of products by Runcangsheng which we did not own in the second quarter of 2022. For the three months ended June 30, 2023, we had $1,085,527 in product revenues (of which $692,709 were from direct sales, $305,186 were from sales at our pharmacies and $87,632 from manufacture and sale) and hotel revenue of $390,530. For three months ended of June 30, 2022, we had $210,636 product revenues (of which $16,591 were from direct sales and $194,045 represented sales at our pharmacies), and hotel revenue of $210,251.

Operation Costs and Expenses

Cost of Goods Sold

Cost of goods sold was $451,200 for the three months ended June 30, 2023, compared to $153,998 for the three months ended June 30, 2022, an increase of $297,202 or 193%. The increase in our cost of goods sold is attributable to the increase in direct product sales, pharmacy sales and sales by Runcangsheng. The cost of goods sold for our direct product sales as a percentage of sales was 38% in 2023, compared to 23% for 2022. The cost of goods sold for products sold through our pharmacies as a percentage of pharmacy product sales was 60% in 2023, compared to 77% in 2022. The cost of goods sold as a percentage of sales by Runcangsheng was 5% in 2023, and no comparable costs were incurred in the three months ended June 30, 2022 as the acquisition of Runcangsheng was completed in the third quarter of 2022. We were able to lower our cost of goods sold and increase our profit margin significantly as a result of the manufacturing business we acquired when we purchased Runcangsheng, which enabled us to sell products we manufactured ourselves.

Hotel Operating Costs

Hotel operating costs were $462,780 and $418,100 for the three months ended June 30, 2023 and 2022. The increase in hotel operating costs was mainly due to the increase in the hotel sales for the three months ended June 30, 2023.

Operating Expenses

Operating expenses were $666,845 for the three months ended June 30, 2023, compared to $588,027 for the same period of 2022, an increase of $78,818 or 13%. The increase in operating expenses was mainly due to the inclusion of the operating expenses of Runcangsheng.

Loss from Operations

Loss from operations was $104,768 in the three months ended June 30, 2023, compared to $739,238 in the same period of 2022, a decrease of $634,470 or 86%. The decrease in our loss from operations for 2023 was due to the increases in our revenues which decreased the losses from our direct sales activities, pharmacies and hotel, which were partly offset by the loss incurred by our new subsidiary, Runcangsheng. All of our operations were materially adversely impacted by travel and work restrictions imposed in China and Chengdu to limit the spread of COVID-19 in 2022.

Non-operating Income

Non-operating income was $12,129 for the three months ended June 30, 2023, compared to $11,442 for the three months ended June 30, 2022. For the three months ended June 30, 2023, we had interest income of $268 and other income $14,241, partly offset by other expenses of $2,380. For the three months ended June 30, 2022, we had interest income of $1,284 and other income of $10,221, partly offset by other expenses of $63.

31

 

We incurred

Income Tax Expense

Income tax expense was $4,907 and $473 for the three months ended June 30, 2023 and 2022, respectively, an increase of $4,434 or 937% for the three months ended June 30, 2023 compared with the same period of 2022.

Net Loss

Our net loss for the three months ended June 30, 2023 was $97,546, compared to a net loss of $54,387$728,269 in the same period of 2022, a decrease of $630,723 or 87%. The decrease in the three months ended June 30, 2023 was mainly due to the increased sales which was partly offset by increased operating costs and $20,869expenses as explained above.

Six Months ended June 30, 2023 and 2022

The following table sets forth the results of our operations for the periods indicated as a percentage of net revenue, certain columns may not add due to rounding:

  Six Months Ended June 30, 
  2023  2022 
  $  

% of

Revenue

  $  

% of

Revenue

 
Revenue $2,230,770   100% $839,565   100%
Operating costs and expenses  2,887,508   129%  2,350,957   280%
Income (loss) from operations  (656,738)  (29)%  (1,511,392)  (180)%
Non-operating income, net  34,772   2%  32,007   4%
Loss before income tax  (621,966)  (28)%  (1,479,385)  (176)%
Income tax expense  5,364   -%  965   -%
Net loss $(627,330)  (28)% $(1,480,350)  (176)%

The following table shows our operations by business segment for the six months ended NovemberJune 30, 20172023 and 2016, respectively. We incurred net loss of $20,500 and $11,949 for the three months ended November 30, 2017 and 2016, respectively.

Our expenses during the periods reported on herein, were primarily2022. Because Runcangsheng was acquired in September 2022, it did not contribute to maintain our corporate existence, file reports with the Securities and Exchange Commission, including the preparation and audit of our financial statements, and expenses associated with finding an appropriate acquisition candidate. Our expenses have been paid from capital contributions and advances from affiliates of the Company.

Liquidity and Capital Resources

As of November 30, 2017, we had $0 in cash. We have financed our operations primarily from advances from related parties. At November 30, 2017, the balance due to our shareholders and officer was $248,265, which was payable on demand without interest. Since we have no cash, we cannot satisfy our cash requirements and need to obtain financing. We cannot assure investors that adequate financing will be available. In the absence of such financing, we may be unable to proceed with our plan of operations.

At November 30, 2017 and May 31, 2017, the amounts due to related parties was $248,265 and $166,677, respectively.

Contractual Obligations

At November 30, 2017, our obligations were: accounts payable, loan due to stockholders and officer, and advance from a third party for paying the company’s operating expenses of $259,292.

Off-Balance Sheet Arrangements

We do not maintain any off-balance sheet arrangements, transactions, obligations or other relationships with unconsolidated entities that would be expected to have a material current or future effect upon our financial condition or results of operations.

Critical Accounting Policies and Estimates

Going Concern

As shown in the accompanying financial statements, at November 30, 2017, we had no cash, a deficit working capital of $259,292 and stockholders’ deficit of $259,292, and a net loss of $54,387 for the six months ended NovemberJune 30, 2017,2022.

  For the Six Months Ended June 30, 
  2023  2022 
Net revenue        
Products $855,969  $32,689 
Pharmacies  528,702   352,939 
Hotel  722,947   453,937 
Manufacture and sale  123,152   - 
Total revenues, net $2,230,770  $839,565 
         
Operating costs and expenses        
Products        
Cost of goods sold $299,528  $8,418 
Operating expenses  828,044   660,261 
Pharmacies        
Cost of goods sold  320,508   270,104 
Operating expenses  246,194   323,151 
Hotel        
Hotel operating costs  940,574   929,719 
Operating expenses  44,360   159,304 
Manufacture and sale        
Cost of goods sold  6,652   - 
Operating expenses  201,648   - 
Total operating costs and expenses $2,887,508  $2,350,957 
         
Loss from operations        
Products $(271,603) $(635,990)
Pharmacies  (38,000)  (240,316)
Hotel  (261,987)  (635,086)
Manufacture and sale  (85,148)  - 
Loss from operations $(656,738) $(1,511,392)

32

Revenue

Revenue was $2,230,770 in the six months ending June 30, 2023, compared to $839,565 in the same period of 2022, an increase of $1,391,205 or 166%. Revenue in the 2nd quarter of 2023 was $1,476,057, an increase of 96% from revenues of $754,713 in the first quarter of 2023. The increase in revenue was mainly due to increases in direct sales of our nutritional products, increases in revenues from our hotel and pharmacies, and the generation of revenue from the manufacture and sale of products by Runcangsheng which we did not own in the first six months of 2022. For the six months ended of June 30, 2023, we had $1,507,823 in product revenues (of which $855,969 were from direct sales, $528,702 were from sales at our pharmacies and $123,152 from manufacture and sale) and hotel revenue of $722,947. For the six months ended of June 30, 2022, we had $385,628 product revenues (of which $32,689 were from direct sales and $352,939 represented sales at our pharmacies), and hotel revenue of $453,937.

Operation Costs and Expenses

Cost of Goods Sold

Cost of goods sold was $626,688 for the six months ended June 30, 2023, compared to $278,522 for the six months ended June 30, 2022, an increase of $348,166 or 125%. The increase in our cost of goods sold is attributable to the increase in direct product sales, pharmacy sales and sales by Runcangsheng. The cost of goods sold for our direct product sales as a percentage of sales was 35% in 2023, compared to 26% for 2022. The cost of goods sold for products sold through our pharmacies as a percentage of pharmacy product sales was 61% in 2023, compared to 77% in 2022. The cost of goods sold as a percentage of sales by Runcangsheng was 5% in 2023, and no comparable costs were incurred in the six months ended June 30, 2022 as the acquisition of Runcangsheng was completed in the third quarter of 2022. We were able to lower our cost of goods sold and increase our profit margin significantly as a result of the manufacturing business we acquired when we purchased Runcangsheng, which enabled us to sell products we manufactured ourselves.

Hotel Operating Costs

Hotel operating costs were $940,574 and $929,719 for the six months ended June 30, 2023 and 2022. The increase in hotel operating costs was mainly due to the increase in hotel sales but was partly offset by decreases in the cost of food and fruits.

Operating Expenses

Operating expenses were $1,320,246 for the six months ended June 30, 2023, compared to $1,142,716 for the same period of 2022, an increase of $177,530 or 16%. The increase in operating expenses was mainly due to the inclusion of the operating expenses of Runcangsheng.

Loss from Operations

Loss from operations was $656,738 in the six months ended June 30, 2023, compared to $1,511,392 in the same period of 2022, a decrease of $854,654 or 57%. The decrease in our loss from operations for 2023 was due to the increases in our revenues which decreased the losses from our direct sales activities, pharmacies and hotel, which were partly offset by the loss incurred by our new subsidiary, Runcangsheng. All of our operations were materially adversely impacted by travel and work restrictions imposed in China and Chengdu to limit the spread of COVID-19 in 2022.

33

Non-operating Income

Non-operating income was $34,772 for the six months ended June 30, 2023, compared to $32,007 for the six months ended June 30, 2022. For the six months ended June 30, 2023, we had interest income of $557 and other income $39,102, partly offset by other expenses of $4,887. For the six months ended June 30, 2022, we had interest income of $2,612 and other income of $29,655, partly offset by other expenses of $260.

Income Tax Expense

Income tax expense was $5,364 and $965 for the six months ended June 30, 2023 and 2022, respectively, an increase of $4,399 or 456% for the six months ended June 30, 2023 compared with the same period of 2022.

Net Loss

Our net loss for the six months ended June 30, 2023 was $627,330, compared to a net loss of $1,480,350 in the same period of 2022, a decrease of $853,020 or 58%. The decrease in the six months ended June 30, 2023 was mainly due to the increased sales which was partly offset by increased operating costs and expenses as explained above.

Liquidity and Capital Resources

During the six months ended June 30, 2023, we used $350,760 in operations. As of June 30, 2023, cash and cash equivalents were $316,905 (excluding $97,625 of restricted cash), compared to $510,128 (excluding $109,772 of restricted cash) as of December 31, 2022. At June 30, 2023, we had a working capital deficit of $2,893,918 compared to $3,346,358 at December 31, 2022.

The following is a summary of cash provided by or used in each of the indicated types of activities during the six months ended June 30, 2023 and 2022, respectively.

  June 30, 2023  June 30, 2022 
Net cash used in operating activities $(350,760) $(771,496)
Net cash used in investing activities $(16,666) $- 
Net cash provided by financing activities $183,977  $779,015 

Net cash used in operating activities

For the six months ended June 30, 2023, net cash used in operating activities was $350,760. This reflects our net loss of $627,330, adjusted by non-cash related expenses including depreciation and amortization expense of $193,427, change in deferred tax of $902, bad debt reversal of $51,853, inventory impairment of $12,026, operating lease expense of $417,369 and stock-based compensation of $185,770, and then decreased by changes in working capital of $481,081. The cash outflow from changes in working capital mainly resulted from increases in other receivables and prepaid expense of $46,276, in unearned revenue of $6,552, in inventory of $170,052, in accounts payable from related party of $165,172, and in accrued liabilities and other payable of $65,670, and payments of lease liabilities of $405,079, partly offset by cash inflows from accounts receivable of $249,851, cash inflows from advances to suppliers, including related party of $24,890, cash inflows from accounts payable of $98,150 and taxes payable of $4,839.

For the six months ended June 30, 2022, net cash used in operating activities was $771,496. This reflects our net loss of $1,480,350, adjusted by non-cash related expenses including depreciation and amortization expense of $57,219, the change in deferred tax of $965, bad debt expense of $47,857, operating lease expense of $449,445 and stock-based compensation of $185,770, and then decreased by changes in working capital of $32,402. The cash outflow from changes in working capital mainly resulted from an increase in accounts receivable of $65,284, payments of lease liabilities of $418,711, a change in inventory of $72,168, unearned revenue of $10,099 and taxes payable of $7,034, which was partly offset by cash inflow from accrued liability and other payables of $346,883, other receivable and prepaid expense of $92,619, accounts payable of $89,349 and advances to suppliers of $12,043.

34

Net cash used in investing activities

For the six months ended June 30, 2023 and 2022, net cash used in investing activities was $16,666 and $0. For the six months ended June 30, 2023, net cash used in investing activities included $10,627 for the purchase of fixed assets, $2,647 for the purchase of intangible assets, and $3,392 cash disposed of at the termination of a non-operating subsidiary.

Net cash provided by financing activities

For the six months ended June 30, 2023, net cash provided by financing activities were the result of advances from related parties of $39,677 and capital contributions of $144,300.

For the six months ended June 30, 2022, net cash provided by financing activities were the result of advances from related parties of $779,015.

We substantially depleted our available cash and working capital during 2022 supporting our operations and completing the acquisition of Runcangsheng and generated a $656,738 loss from operations in the first six months of 2023. It is likely that Runcangsheng will require additional capital to achieve its short term operational goals and long range business plans. Further, we may need additional capital to maintain our other businesses. We may also have to raise additional financing as our working capital requirements are expected to increase in line with the growth of our business as a result of our acquisition of Runcangsheng. In the past we have funded our operations through proceeds from private placements of equity and advances from our principal shareholder. Should we require capital to fund our business, we intend to finance our business by raising additional capital or, when available, borrowing additional funds. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders and could cause the price of our common stock to decrease. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

We are subject to all of the substantial doubt aboutrisks inherent in the development of a new business enterprise within an extremely competitive industry. Due to the absence of a long-standing operating history and the emerging nature of the markets in which we compete, we anticipate operating losses until we can successfully implement our business strategy. Our revenue model is new and evolving, and we cannot be certain that it will be successful. The potential profitability of our business model is unproven. We may never ever achieve profitable operations. Our future operating results depend on many factors, including demand for our services, the level of competition, and the ability of our officers to manage our business and growth. As a result of the emerging nature of the market in which we compete, we may incur operating losses until such time as we can develop a substantial and stable revenue base. Additional development expenses may delay or negatively impact the ability of the Company to generate profits. Accordingly, we cannot assure you that our business model will be successful or that we can sustain revenue growth, achieve or sustain profitability, or continue as a going concern.

The report of our independent registered public accountants on our financial statements as of and for the year ended May 31, 2017 states that these conditions, among others, raise substantial doubt about ourOur ability to continue as a going concern. Our financial statements do not include any adjustments relating toobtain funds through the recoverability and classificationissuance of recorded assets,debt or the amount and classification of liabilities that might be necessary in the event we cannot continue as a going concern.

Our future successequity is dependent upon among other things, our abilitythe state of the financial markets at such time as we may seek to raise additionalfunds. The state of the capital ormarket markets may be adversely impacted by various risks and uncertainties, including, but not limited to secure a future business combination. There is no guaranteeand current impacts of global events such as COVID-19 and the war in the Ukraine, increases in inflation and other risks detailed herein.

Impact of Inflation

Our results of operations may be affected by inflation, particularly rising prices for products and other operating costs if we cannot pass such increases along to our customers in the form of higher prices for our products and services. Generally, we are not party to long term contracts and our inventory turns multiple times per year and we anticipate that we will be able to raise enough capital or generate revenuesincrease prices on products to sustain our operations. Our management believes it can raise the appropriate funds needed to support its business plan and acquire an operating company with positive cash flow.

Recent Accounting Pronouncements

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies the presentation and classification of certain cash receipts and cash paymentsreflect increases in the statementcost of cash flows. This ASU is effective for public business entities for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. The Company does not anticipate the adoption of this ASU will have a significant impact on its financial statementsinventory.

1435

 

Contractual Obligations

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The guidance requires that a statement of cash flows explain the change during the period

We have no long-term fixed contractual obligations or commitments.

Contingencies

Our operations are conducted in the totalPRC and are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments in China and foreign currency exchange rates. Our results may be adversely affected by changes in PRC government policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad and rates and methods of cash, cash equivalents,taxation, among other things.

Our sales, purchases and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cashexpense transactions in China are denominated in RMB and restricted cash equivalents shouldall of our assets and liabilities in China are also denominated in RMB. The RMB is not freely convertible into foreign currencies under the current PRC law. In China, foreign exchange transactions are required by law to be included with cashtransacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain supporting documentation in order to affect the remittance.

Significant Accounting Policies

Our management’s discussion and cash equivalents when reconciling the beginning-of-periodanalysis of our financial condition and end-of-period total amounts shown on the statement of cash flows. The standard is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The standard should be applied using a retrospective transition method to each period presented. The Company does not anticipate the adoption of this ASU will have a significant impact on its financial statements.

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The standard should be applied prospectively on or after the effective date. The Company does not anticipate the adoption of this ASU will have a significant impact on its financial statements.

The Company has reviewed all other recently issued but not yet effective accounting pronouncements and have determined that these new accounting pronouncements are either not applicable or would not have a material impact on its results of operations are based on our consolidated financial statements, which were prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported net sales and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and assumptions. We base our estimates on historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 2 to our consolidated financial position.statements, we believe the following accounting policies are the most critical to assist you in fully understanding and evaluating this management discussion and analysis.

Item 3. QuantitativeBasis of Presentation

The accompanying financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”). The functional currency of AiXinZhonghong, Aixin Shangyan Hotel, Aixintang Pharmacies and Qualitative Disclosures About Market Risk.Runcangsheng is the Chinese Renminbi (“RMB”). The accompanying financial statements are translated from RMB and presented in U.S. dollars (“USD”).

As a smallerUse of Estimates

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting company, the Company is not required to provide the informationperiod.

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

36

Accounts Receivable

We maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of June 30, 2023 and December 31, 2022, the bad debt allowance was $200,044 and $272,550, respectively.

Revenue Recognition

Revenue from sale of goods under Topic 606 is recognized in a manner that reasonably reflects the delivery of our products and services to customers in return for expected consideration and includes the following elements:

executed contract(s) with customers that we believe are legally enforceable;
identification of performance obligation in the respective contract;
determination of the transaction price for each performance obligation in the respective contract;
allocation of the transaction price to each performance obligation; and
recognition of revenue only when we satisfy each performance obligation.

Our revenue recognition policies for our operating segments are as follows:

Products

Our revenue from sales of products is recognized when goods are delivered to the customer and no other obligation exists. We do not provide unconditional return or other concessions to customers. Our sales policy allows for the return of unopened products for cash after deducting certain service and transaction fees. As an alternative to returning a product, customers may request an exchange for products with the same value.

Product sales revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of our products sold in China are subject to the PRC VAT of 17% of the gross sales price prior to May 1, 2018, 16% since May 1, 2018 and 13% since April 1, 2019. This VAT may be offset by VAT paid by for raw materials and other materials purchased in China. We record VAT payables and VAT receivables net of payments in the financial statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as we act as an agent for the government.

Pharmacies

Our retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation. We generally receive payment from pharmacy customers we satisfy our performance obligations. We record a receivable when we have an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of VAT. All of the products sold in our pharmacies are exempt from VAT as the pharmacies qualify for a small business exemption.

37

Manufacture and Sale

The Company’s new subsidiary Runcangsheng recognizes revenue at the time products are shipped as this Item.satisfies its performance obligation. The Company records a receivable for the sales when it has an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of the Company’s products sold in China are subject to the PRC VAT of 13% unless it is a qualified small business subject to exemption.

Hotel

Hotel revenues are primarily derived from the rental of rooms, food and beverage sales and other ancillary goods and services, including but not limited to souvenir, parking and conference reservations. Each of these products and services represents a distinct performance obligation and, in exchange for these services, we receive fixed amounts based on published rates or negotiated contracts. Payment is due in full at the time when the services are rendered or the goods are provided. Room rental revenue is recognized on a daily basis when rooms are occupied. Food and beverage revenue and other goods and services revenue are recognized when they have been delivered or rendered to the guests as the respective performance obligations are satisfied. All of the hotel’s goods sold in China are subject to the PRC VAT of 6%. This VAT may be offset by VAT paid by on raw materials and other materials purchased in China.

 

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintainManagement of AiXin Life International, Inc. is responsible for maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in ourthe reports that we file or submit under the Securities Exchange Act reportsof 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms,forms. In addition, the disclosure controls and procedures must ensure that such information is accumulated and communicated to our management, including theour Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management necessarily applies its judgment in assessing the costsfinancial and benefitsother required disclosures.

An evaluation of such controls and procedures, which, by their nature, can provide only reasonable assurance regarding management’s control objectives.

During the quarter ended February 28, 2017, there was a change in control of our Company as a result of the sale of more than 95% of our shares currently outstanding. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e)Rules 13(a)-15(e) and 15(d)-15(e) of the Exchange Act as of June 30, 2023, was carried out under the Exchange Act) assupervision and with the participation of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that the design and operationOfficer. Based on their evaluation of our disclosure controls and procedures, were not effective as ofthey concluded that at June 30, 2023, such date to provide assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding disclosure. The principal deficiency in ourdisclosure controls and procedures derives fromwere not effective. This was due to our limited resources, including the lackabsence of familiaritya financial staff with accounting and financial expertise and deficiencies in the design or operation of currentour internal control over financial reporting that adversely affected our disclosure controls and that may be considered to be “material weaknesses.”

We plan to designate individuals responsible for identifying reportable developments and to implement procedures designed to remediate the material weakness by focusing additional attention and resources in our internal accounting functions. However, the material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management with U. S. Securities Laws and Regulations and applicable accounting standards.has concluded, through testing, that these controls are operating effectively.

15

Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter which is the subject of this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

38

 

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

There is no pending litigation to which the Company is presently a party or to which the Company’s property is subject and management is not aware of any litigation which may arise in the future.

Item 1A. Risk Factors

Reference is made to the risks and uncertainties disclosed in Item 1A (“Risk Factors”Factors) of our Current Report2022 Form 10-K and in the “Risk Factors” section in our registration Statement on Form 8-K reporting the acquisition of AiXin (BVI) International Group Co., Ltd. filedS-1, as amended on December 14, 2017July 25, 2023 (the “Form 8-K”“Registration Statement”), which are incorporated by reference into this report. Prospective investors are encouraged to consider the risks described in the 20172022 Form 8-K,10-K, the Registration Statement, Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in the Form 8-Kthis report and other information publicly disclosed or contained in documents we file with the Securities and Exchange Commission before purchasing our securities.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the quarter ended November 30, 2017, we did not have any sales of equity securities in transactions that were not registered under the Securities Act of 1933, as amended, that have not been previously reported in a Form 8-K.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

N/A.

Item 5. Other Information

On December 12, 2017, we entered into and closed a share exchange agreement, or the Share Exchange Agreement, with AiXin (BVI) International Group Co., Ltd. a British Virgin Islands corporation (“AiXin BVI”), and Quanzhong Lin, the sole stockholder of AiXin BVI (the “AiXin BVI Stockholder”), pursuant to which we acquired 100% of the outstanding capital stock of AiXin BVI for 227,352,604 shares of our common stock (the “Share Exchange” or the “AiXin Acquisition”). The foregoing description of the terms of the Share Exchange Agreement is qualified in its entirety by reference to the provisions of the Share Exchange Agreement filed as Exhibit 2.1 to the Form 8-K. After giving effect to the Share Exchange, we had outstanding 317,988,089 shares of common stock.

As a result of the Share Exchange, AiXin BVI became our wholly-owned subsidiary, and we now own all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”), which in turn owns all of the outstanding shares of Chengdu AiXin Zhonghong Biological Technology Co., Ltd., a Chinese limited company (“AiXin Zhonghong”), which markets and sells innovative, premium-quality nutritional products in Chengdu, China. For additional information concerning the business of AiXin Zhonghong, see the Form 8-K.

16

Prior to the AiXin Acquisition, Quanzhong Lin, our President and Chief Executive Officer, owned all of the outstanding shares of AiXin BVI and 29,521,410 shares of our common stock, approximately 65% of the outstanding shares of Mercari Communications Group, Ltd. As a result of the Share Exchange, Mr. Lin now owns 256,874,014 shares of our common stock, 80.78% of our outstanding shares, after giving effect to certain other issuances described in the Form 8-K under the caption “Market for Registrant’s Common Equity and Related Stockholder Matters.”

For accounting purposes, the acquisition has been accounted for as a reverse acquisition and has been treated as a recapitalization of Mercari Communications Group, Ltd. effected by a share exchange, with AiXin BVI as the accounting acquirer. Since neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017, the historical financial statements of AiXin Zhonghong are now the historical financial statements of the registrant, Mercari Communications Group, Ltd., and have been included in Item 9.01(a) of the Form 8-K. The assets and liabilities of AiXin Zhonghong have been brought forward at their book value and no goodwill has been recognized.

We have filed an amendment to our Articles of Incorporation changing our corporate name to AiXin Life International, Inc. (the “Name Change Amendment”), which is expected to become effective on or about February 1, 2018, subject to approval by the Financial Regulatory Authority, or FINRA. The Name Change Amendment was approved by written consent of shareholders owning a majority of our outstanding shares and we have filed with the SEC and mailed to our shareholders an Information Statement with respect to the Name Change Amendment.

Item 6. Exhibits

Exhibit
Number

No.

Description of Exhibit
2.131.1Share Exchange Agreement, dated as of December 12, 2017, among the Company, AiXin BVI, AiXin HK, AiXin Zhonghong and the stockholders of Aixin Zhonghong (incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on December 14, 2017).
3.1Articles of Incorporation (incorporated by reference to the Company’s Annual Report on Form 10-KSB for the fiscal year ended May 31, 2006 as filed with the SEC on March 7, 2007).
3.2Articles of Amendment to Articles of Incorporation (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 3, 2008).
3.3Articles of Amendment to Articles of Incorporation changing the name of the Company to AiXin Life International, Inc.
3.4Bylaws of the Registrant (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 3, 2008).
10.1Stock Purchase Agreement dated December 20, 2016, between Algodon and China Concentric, as amended (incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on December 14, 2017).
10.2Stock Purchase Agreement dated December 21, 2016, between China Concentric and Quanzhong Lin (incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on December 14, 2017).
31.1Certification of the PrincipalChief Executive Officer Pursuantpursuant to Section 302Rule 13a-14 or Rule 15d-14 of the Sarbanes-OxleySecurities Exchange Act of 2002.1934.
31.2Certification of the PrincipalChief Financial Officer Pursuantpursuant to Section 302Rule 13a-14 or Rule 15d-14 of the Sarbanes-OxleySecurities Exchange Act of 2002.1934.
32.1Certification of the PrincipalChief Executive Officer Pursuantpursuant to Section 906 of the Sarbanes-Oxley Act of 2002.2002 (18 U.S.C. Section 1350).
32.2Certification of the PrincipalChief Financial Officer Pursuantpursuant to Section 906 of the Sarbanes-Oxley Act of 2002.2002 (18 U.S.C. Section 1350).
101.INSInline XBRL Instance Document
101.SCHInline XBRL Taxonomy Extension Schema
101.CALInline XBRL Taxonomy Extension Calculation
101.DEFInline XBRL Taxonomy Extension Definition
101.LABInline XBRL Taxonomy Extension Label
101.PREInline XBRL Taxonomy Extension Presentation
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

101.INS XBRL Instance Document

101.SCH XBRL Schema Document

101.CAL XBRL Calculation Linkbase Document

101.DEF XBRL Definition Linkbase Document

101.LAB XBRL Label Linkbase Document

101.PRE XBRL Presentation Linkbase Document

1739

 

SIGNATURES

SIGNATURES

Pursuant to the requirements of section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MERCARI COMMUNICATIONS GROUP, LTD.AIXIN LIFE INTERNATIONAL, INC.
Dated: January 16, 2018August 18, 2023By:/s/ Quanzhong Lin
Quanzhong Lin
President and Chief Executive Officer
(Principal Executive Officer)

1840